



US011865287B2

(12) **United States Patent**  
**Ignon et al.**

(10) **Patent No.:** **US 11,865,287 B2**  
(45) **Date of Patent:** **\*Jan. 9, 2024**

(54) **DEVICES AND METHODS FOR TREATING SKIN**

(71) Applicant: **HydraFacial LLC**, Long Beach, CA (US)

(72) Inventors: **Roger Ignon**, Redondo Beach, CA (US); **Scott Mallett**, Coto De Caza, CA (US); **Abraham Solano**, Corona, CA (US); **William Cohen**, Los Alamitos, CA (US)

(73) Assignee: **HydraFacial LLC**, Long Beach, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **18/094,884**

(22) Filed: **Jan. 9, 2023**

(65) **Prior Publication Data**

US 2023/0158282 A1 May 25, 2023

**Related U.S. Application Data**

(63) Continuation of application No. 17/165,820, filed on Feb. 2, 2021, now Pat. No. 11,547,840, which is a (Continued)

(51) **Int. Cl.**  
**A61M 35/00** (2006.01)  
**A61B 17/54** (2006.01)  
(Continued)

(52) **U.S. Cl.**  
CPC ..... **A61M 35/003** (2013.01); **A61B 17/3205** (2013.01); **A61B 17/50** (2013.01);  
(Continued)

(58) **Field of Classification Search**

CPC ... A61B 17/3205; A61B 17/54; A61B 17/545; A61B 2017/00199; A61B 2017/00761;  
(Continued)

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

1,651,585 A 12/1927 Clair  
D117,295 S 10/1939 Smith  
(Continued)

**FOREIGN PATENT DOCUMENTS**

AT 400305 12/1995  
AU 1014299 5/1999  
(Continued)

**OTHER PUBLICATIONS**

Amazon, Fazjeune 7 Color LED Light, LED Face Mask Skin Rejuvenation PDT Photon Facial Skin Care Mask Skin Tightening Lamp SPA Face Device Beauty Salon Equipment Anti-aging RemoveWrinkle, Customer reviewed on Sep. 2020, retrieved from internet at [https://www.amazon.com/FAZJEUNE-Rejuvenation-Tightening-Equipment-Anti-aging/dp/B08B4M8RQQ/ref=psdc\\_11061121\\_13\\_B08ZSPZSF4](https://www.amazon.com/FAZJEUNE-Rejuvenation-Tightening-Equipment-Anti-aging/dp/B08B4M8RQQ/ref=psdc_11061121_13_B08ZSPZSF4).

(Continued)

*Primary Examiner* — Darwin P Erezzo


*Assistant Examiner* — Christian D Knauss

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(57) **ABSTRACT**

An apparatus for treating skin has a console with a user input device and a handpiece assembly. The handpiece assembly is configured to treat skin. A fluid line provides fluid communication between the console and the handpiece assembly. A manifold system is coupled to the console and controlled by the user input device. The manifold system is

(Continued)



configured to hold releasably a plurality of fluid sources and deliver fluid from at least one of the plurality of fluid sources to the handpiece assembly.

#### 45 Claims, 25 Drawing Sheets

#### Related U.S. Application Data

continuation of application No. 16/517,268, filed on Jul. 19, 2019, now Pat. No. 11,446,477, which is a continuation of application No. 15/660,777, filed on Jul. 26, 2017, now Pat. No. 10,357,642, which is a continuation of application No. 15/660,750, filed on Jul. 26, 2017, now Pat. No. 10,357,641, which is a continuation of application No. 14/700,789, filed on Apr. 30, 2015, now Pat. No. 9,814,868, which is a continuation of application No. 14/698,713, filed on Apr. 28, 2015, now Pat. No. 9,662,482, which is a continuation of application No. 14/698,673, filed on Apr. 28, 2015, now Pat. No. 9,550,052, which is a continuation of application No. 13/267,554, filed on Oct. 6, 2011, now Pat. No. 9,474,886, which is a continuation of application No. 11/392,348, filed on Mar. 29, 2006, now Pat. No. 8,048,089.

- (60) Provisional application No. 60/764,668, filed on Feb. 2, 2006, provisional application No. 60/755,310, filed on Dec. 30, 2005.

#### (51) Int. Cl.

*A61B 50/10* (2016.01)  
*A61B 50/13* (2016.01)  
*A61M 1/00* (2006.01)  
*A61B 17/3205* (2006.01)  
*A61B 17/50* (2006.01)  
*A61M 37/00* (2006.01)  
*A61B 17/00* (2006.01)  
*A61N 5/06* (2006.01)  
*A61B 17/32* (2006.01)

#### (52) U.S. Cl.

CPC ..... *A61B 17/54* (2013.01); *A61B 17/545* (2013.01); *A61B 50/10* (2016.02); *A61B 50/13* (2016.02); *A61M 1/962* (2021.05); *A61M 37/00* (2013.01); *A61B 2017/00199* (2013.01); *A61B 2017/00761* (2013.01); *A61B 2017/320004* (2013.01); *A61B 2217/005* (2013.01); *A61M 2037/0007* (2013.01); *A61N 5/0616* (2013.01)

#### (58) Field of Classification Search

CPC .. *A61B 2017/320004*; *A61B 2217/005*; *A61B 2217/007*; *A61M 1/774*  
 See application file for complete search history.

#### (56) References Cited

##### U.S. PATENT DOCUMENTS

D151,807 S 11/1948 Berkowitz  
 2,608,032 A 8/1952 Garver  
 2,631,583 A 3/1953 Lavergne  
 2,701,559 A 2/1955 Cooper  
 2,712,823 A 7/1955 Kurtin  
 2,867,214 A 1/1959 Wilson  
 2,881,763 A 4/1959 Robbins  
 2,921,585 A 1/1960 Schumann  
 3,037,509 A 6/1962 Schutz

3,085,573 A 4/1963 Meyer et al.  
 3,214,869 A 11/1965 Stryker  
 3,468,079 A 9/1969 Kaufman  
 3,476,112 A 11/1969 Elstein  
 3,481,677 A 12/1969 Abrahamson  
 3,505,993 A 4/1970 Lewes et al.  
 3,560,100 A 2/1971 Spatz  
 3,574,239 A 4/1971 Sollerud  
 3,608,553 A 9/1971 Balamuth  
 3,715,838 A 2/1973 Young et al.  
 3,865,352 A 2/1975 Nelson et al.  
 3,866,264 A 2/1975 Engquist  
 D237,776 S 11/1975 Arassa et al.  
 D237,863 S 12/1975 Peters et al.  
 3,930,598 A 1/1976 Slagle  
 3,948,265 A 4/1976 Al Ani  
 3,964,212 A 6/1976 Karder  
 3,968,789 A 7/1976 Simoncini  
 3,977,084 A 8/1976 Sloan  
 4,121,388 A 10/1978 Wilson  
 4,155,721 A 5/1979 Fletcher  
 4,170,821 A 10/1979 Booth  
 4,182,329 A 1/1980 Smit et al.  
 4,203,431 A 5/1980 Abura et al.  
 D255,325 S 6/1980 Hoyt  
 4,216,233 A 8/1980 Stein  
 4,225,254 A 9/1980 Holberg et al.  
 D258,348 S 2/1981 Hoyt  
 D259,921 S 7/1981 Hartmann  
 D260,176 S 8/1981 Boschetti et al.  
 4,289,158 A 9/1981 Nehring  
 4,299,219 A 11/1981 Norris, Jr.  
 4,342,522 A 8/1982 Mackles  
 4,378,804 A 4/1983 Cortese  
 4,500,222 A 2/1985 Clading-Boel  
 4,560,373 A 12/1985 Sugino et al.  
 D288,293 S 2/1987 Arvans  
 4,646,480 A 3/1987 Williams  
 4,646,482 A 3/1987 Chitjian  
 4,655,743 A 4/1987 Hyde  
 4,671,412 A 6/1987 Gatten  
 4,676,749 A 6/1987 Mabile  
 D290,999 S 7/1987 Novak  
 4,706,676 A 11/1987 Peck  
 4,718,467 A 1/1988 Di Gianfilippo et al.  
 4,754,756 A 7/1988 Shelanski  
 4,757,814 A 7/1988 Wang et al.  
 4,764,362 A 8/1988 Barchas  
 4,795,421 A 1/1989 Blasius, Jr. et al.  
 4,811,734 A 3/1989 McGurk-Burleson et al.  
 4,836,192 A 6/1989 Abbate  
 4,866,202 A 9/1989 Weil  
 4,875,287 A 10/1989 Creasy et al.  
 4,886,078 A 12/1989 Shiffman  
 4,887,994 A 12/1989 Bedford  
 4,900,316 A 2/1990 Yamamoto  
 4,917,086 A 4/1990 Feltovich et al.  
 4,925,450 A 5/1990 Imonti et al.  
 D308,480 S 6/1990 Hoyt  
 4,940,350 A 7/1990 Kim  
 4,957,747 A 9/1990 Stiefel  
 4,990,841 A 2/1991 Elder  
 5,006,004 A 4/1991 Dirksing et al.  
 5,006,339 A 4/1991 Bargery et al.  
 5,012,797 A 5/1991 Clarke  
 D317,719 S 6/1991 Hestehave et al.  
 5,035,089 A 7/1991 Tillman et al.  
 5,037,431 A 8/1991 Summers et al.  
 5,037,432 A 8/1991 Molinari  
 5,054,339 A 10/1991 Yacowitz  
 5,100,412 A 3/1992 Rosso  
 5,100,424 A 3/1992 Jang  
 5,119,839 A 6/1992 Rudolph  
 5,122,153 A 6/1992 Harrel  
 5,171,215 A 12/1992 Flanagan  
 5,192,269 A 3/1993 Poli et al.  
 5,207,234 A 5/1993 Rosso  
 5,217,455 A 6/1993 Tan  
 5,222,956 A 6/1993 Waldron

(56)

## References Cited

## U.S. PATENT DOCUMENTS

|             |         |                  |               |         |                                       |
|-------------|---------|------------------|---------------|---------|---------------------------------------|
| 5,242,433 A | 9/1993  | Smith et al.     | 6,120,512 A   | 9/2000  | Bernabei                              |
| 5,254,109 A | 10/1993 | Smith et al.     | 6,129,701 A   | 10/2000 | Cimino                                |
| 5,290,273 A | 3/1994  | Tan              | 6,136,008 A   | 10/2000 | Becker et al.                         |
| 5,368,581 A | 11/1994 | Smith et al.     | 6,139,553 A   | 10/2000 | Dotan                                 |
| 5,387,215 A | 2/1995  | Fisher           | 6,139,554 A   | 10/2000 | Karkar et al.                         |
| 5,391,151 A | 2/1995  | Wilmot           | 6,142,155 A   | 11/2000 | Rudolph                               |
| 5,417,674 A | 5/1995  | Smith et al.     | 6,149,634 A   | 11/2000 | Bernabei                              |
| 5,419,772 A | 5/1995  | Teitz et al.     | 6,149,644 A   | 11/2000 | Xie                                   |
| 5,423,803 A | 6/1995  | Tankovich et al. | 6,159,226 A   | 12/2000 | Kim                                   |
| 5,437,372 A | 8/1995  | Per-Lee          | 6,162,218 A   | 12/2000 | Elbrecht et al.                       |
| 5,441,490 A | 8/1995  | Svedman          | 6,162,232 A * | 12/2000 | Shaddock ..... A61B 17/545<br>604/289 |
| 5,460,620 A | 10/1995 | Smith et al.     | 6,165,059 A   | 12/2000 | Park et al.                           |
| 5,470,323 A | 11/1995 | Smith et al.     | 6,174,325 B1  | 1/2001  | Eckhouse                              |
| 5,484,427 A | 1/1996  | Gibbons          | 6,176,198 B1  | 1/2001  | Kao et al.                            |
| 5,490,736 A | 2/1996  | Haber et al.     | 6,183,451 B1  | 2/2001  | Mehl, Sr. et al.                      |
| 5,512,044 A | 4/1996  | Duer             | 6,183,483 B1  | 2/2001  | Chang                                 |
| 5,562,642 A | 10/1996 | Smith et al.     | 6,190,376 B1  | 2/2001  | Asah et al.                           |
| 5,562,643 A | 10/1996 | Johnson          | 6,193,589 B1  | 2/2001  | Khalaj                                |
| 5,611,687 A | 3/1997  | Wagner           | 6,196,982 B1  | 3/2001  | Ball                                  |
| 5,612,797 A | 3/1997  | Clarke           | 6,231,593 B1  | 5/2001  | Meserol                               |
| 5,618,275 A | 4/1997  | Bock             | 6,235,039 B1  | 5/2001  | Parkin et al.                         |
| 5,626,631 A | 5/1997  | Eckhouse         | 6,238,275 B1  | 5/2001  | Metcalf et al.                        |
| 5,658,323 A | 8/1997  | Miller           | 6,241,739 B1  | 6/2001  | Waldron                               |
| 5,658,583 A | 8/1997  | Zhang et al.     | 6,245,347 B1  | 6/2001  | Zhang et al.                          |
| 5,674,235 A | 10/1997 | Parisi           | 6,264,666 B1  | 7/2001  | Coleman et al.                        |
| 5,676,643 A | 10/1997 | Cann et al.      | 6,269,271 B1  | 7/2001  | Bernabei                              |
| 5,676,648 A | 10/1997 | Henley           | 6,277,116 B1  | 8/2001  | Utely et al.                          |
| 5,683,971 A | 11/1997 | Rose et al.      | 6,277,128 B1  | 8/2001  | Muldner                               |
| 5,697,920 A | 12/1997 | Gibbons          | 6,280,438 B1  | 8/2001  | Eckhouse et al.                       |
| 5,707,383 A | 1/1998  | Bays             | 6,283,978 B1  | 9/2001  | Cheski et al.                         |
| 5,713,785 A | 2/1998  | Nishio           | 6,284,266 B1  | 9/2001  | Zhang et al.                          |
| 5,735,833 A | 4/1998  | Olson            | 6,299,620 B1  | 10/2001 | Shaddock                              |
| 5,755,751 A | 5/1998  | Eckhouse         | 6,306,119 B1  | 10/2001 | Weber et al.                          |
| 5,759,185 A | 6/1998  | Grinberg         | 6,306,147 B1  | 10/2001 | Bernabei et al.                       |
| 5,762,640 A | 6/1998  | Kajiwaru et al.  | 6,322,548 B1  | 11/2001 | Payne et al.                          |
| 5,779,519 A | 7/1998  | Oliver           | 6,322,568 B1  | 11/2001 | Bernabei et al.                       |
| 5,800,446 A | 9/1998  | Banuchi          | 6,325,381 B1  | 12/2001 | von Engelbrechten                     |
| 5,807,353 A | 9/1998  | Schmitz          | 6,325,769 B1  | 12/2001 | Klopotek                              |
| 5,810,842 A | 9/1998  | Di Fiore et al.  | 6,332,886 B1  | 12/2001 | Green et al.                          |
| 5,813,416 A | 9/1998  | Rudolph          | 6,334,074 B1  | 12/2001 | Spertell                              |
| 5,817,050 A | 10/1998 | Klein            | 6,355,054 B1  | 3/2002  | Neuberger                             |
| 5,817,089 A | 10/1998 | Tankovich et al. | 6,368,333 B2  | 4/2002  | Bernabei et al.                       |
| 5,834,510 A | 11/1998 | Yu et al.        | 6,383,177 B1  | 5/2002  | Balle-Petersen et al.                 |
| 5,846,215 A | 12/1998 | Zygmunt          | 6,387,089 B1  | 5/2002  | Kreindel et al.                       |
| 5,848,998 A | 12/1998 | Marasco, Jr.     | 6,387,103 B2  | 5/2002  | Shaddock                              |
| 5,857,995 A | 1/1999  | Thomas et al.    | 6,401,289 B1  | 6/2002  | Herbert                               |
| 5,861,142 A | 1/1999  | Schick           | 6,409,736 B1  | 6/2002  | Bernabei                              |
| 5,873,881 A | 2/1999  | McEwen et al.    | 6,410,599 B1  | 6/2002  | Johnson                               |
| 5,879,323 A | 3/1999  | Henley           | RE37,796 E    | 7/2002  | Henley                                |
| 5,879,376 A | 3/1999  | Miller           | 6,414,032 B1  | 7/2002  | Johnson                               |
| 5,882,201 A | 3/1999  | Salem            | 6,420,431 B1  | 7/2002  | Johnson                               |
| 5,885,260 A | 3/1999  | Mehl, Sr. et al. | 6,423,078 B1  | 7/2002  | Bays et al.                           |
| 5,908,401 A | 6/1999  | Henley           | 6,423,750 B1  | 7/2002  | Johnson                               |
| 5,911,223 A | 6/1999  | Weaver et al.    | 6,432,113 B1  | 8/2002  | Parkin et al.                         |
| 5,919,152 A | 7/1999  | Zygmunt          | 6,432,114 B1  | 8/2002  | Rosso                                 |
| 5,919,479 A | 7/1999  | Zhang et al.     | 6,458,109 B1  | 10/2002 | Henley et al.                         |
| 5,954,730 A | 9/1999  | Bernabei         | 6,471,712 B2  | 10/2002 | Burres                                |
| 5,971,999 A | 10/1999 | Naldoni          | 6,477,410 B1  | 11/2002 | Henley et al.                         |
| 5,980,555 A | 11/1999 | Barbut et al.    | 6,482,212 B1  | 11/2002 | Bernabei et al.                       |
| 6,019,749 A | 2/2000  | Fields et al.    | 6,488,646 B1  | 12/2002 | Zygmunt                               |
| 6,023,639 A | 2/2000  | Hakky et al.     | 6,494,856 B1  | 12/2002 | Zygmunt                               |
| 6,024,733 A | 2/2000  | Eggers et al.    | 6,500,183 B1  | 12/2002 | Waldron                               |
| 6,027,402 A | 2/2000  | Oliver           | 6,503,256 B2  | 1/2003  | Parkin et al.                         |
| 6,027,495 A | 2/2000  | Miller           | 6,508,813 B1  | 1/2003  | Altshuler                             |
| 6,032,071 A | 2/2000  | Binder           | 6,511,486 B2  | 1/2003  | Mercier et al.                        |
| 6,036,684 A | 3/2000  | Tankovich et al. | 6,514,243 B1  | 2/2003  | Eckhouse et al.                       |
| 6,039,745 A | 3/2000  | Flore et al.     | 6,514,262 B1  | 2/2003  | Di Fiore et al.                       |
| 6,042,552 A | 3/2000  | Cornier          | 6,514,278 B1  | 2/2003  | Hibst et al.                          |
| 6,074,382 A | 6/2000  | Asah et al.      | 6,518,538 B2  | 2/2003  | Bernabei                              |
| 6,080,165 A | 6/2000  | DeJacma          | 6,520,931 B2  | 2/2003  | Suh                                   |
| 6,080,166 A | 6/2000  | McEwen et al.    | D472,136 S    | 3/2003  | Hermann                               |
| D428,142 S  | 7/2000  | Stromblad        | 6,527,716 B1  | 3/2003  | Eppstein                              |
| 6,090,085 A | 7/2000  | Mehl, Sr. et al. | 6,527,783 B1  | 3/2003  | Ignon                                 |
| 6,093,021 A | 7/2000  | Rainey           | 6,533,776 B2  | 3/2003  | Asah et al.                           |
| 6,113,559 A | 9/2000  | Klopotek         | 6,535,761 B2  | 3/2003  | Bernabei                              |
|             |         |                  | 6,537,242 B1  | 3/2003  | Palmer                                |
|             |         |                  | 6,540,757 B1  | 4/2003  | Hruska et al.                         |
|             |         |                  | 6,546,281 B1  | 4/2003  | Zhang et al.                          |

(56)

## References Cited

## U.S. PATENT DOCUMENTS

|           |    |         |                     |           |    |         |                   |
|-----------|----|---------|---------------------|-----------|----|---------|-------------------|
| 6,562,013 | B1 | 5/2003  | Marasco, Jr.        | D533,962  | S  | 12/2006 | Angeletta         |
| 6,562,050 | B1 | 5/2003  | Owen                | 7,153,311 | B2 | 12/2006 | Chung             |
| 6,564,093 | B1 | 5/2003  | Ostrow et al.       | 7,166,086 | B2 | 1/2007  | Haider et al.     |
| 6,565,535 | B2 | 5/2003  | Zalas et al.        | D536,481  | S  | 2/2007  | Angeletta         |
| 6,569,157 | B1 | 5/2003  | Shain et al.        | 7,172,572 | B2 | 2/2007  | Diamond et al.    |
| 6,582,442 | B2 | 6/2003  | Simon et al.        | 7,189,230 | B2 | 3/2007  | Knowlton          |
| 6,587,730 | B2 | 7/2003  | Bernabei            | 7,197,359 | B1 | 3/2007  | Tokudome et al.   |
| 6,589,218 | B2 | 7/2003  | Garcia              | 7,198,623 | B2 | 4/2007  | Fischer et al.    |
| 6,592,595 | B1 | 7/2003  | Mallett et al.      | 7,201,765 | B2 | 4/2007  | McDaniel          |
| 6,595,934 | B1 | 7/2003  | Hissong et al.      | D545,207  | S  | 6/2007  | De Baschmakoff    |
| 6,611,706 | B2 | 8/2003  | Avrahami et al.     | 7,232,431 | B1 | 6/2007  | Weimann           |
| 6,626,445 | B2 | 9/2003  | Murphy et al.       | 7,232,444 | B2 | 6/2007  | Chang             |
| 6,629,927 | B1 | 10/2003 | Mesaros et al.      | 7,241,208 | B2 | 7/2007  | Suissa et al.     |
| 6,629,971 | B2 | 10/2003 | McDaniel            | 7,250,045 | B2 | 7/2007  | Island et al.     |
| 6,629,974 | B2 | 10/2003 | Penny et al.        | D553,005  | S  | 10/2007 | Py et al.         |
| 6,629,983 | B1 | 10/2003 | Ignon               | 7,276,051 | B1 | 10/2007 | Henley et al.     |
| 6,635,035 | B1 | 10/2003 | Marasco et al.      | 7,293,930 | B2 | 11/2007 | Chuang            |
| 6,641,591 | B1 | 11/2003 | Shadduck            | D557,611  | S  | 12/2007 | Ingemarsson       |
| 6,645,184 | B1 | 11/2003 | Zelickson et al.    | 7,314,326 | B2 | 1/2008  | Rosenberg         |
| 6,652,888 | B2 | 11/2003 | Rhoades             | 7,316,657 | B2 | 1/2008  | Kleinhenz et al.  |
| 6,666,874 | B2 | 12/2003 | Heitzmann et al.    | 7,316,671 | B2 | 1/2008  | Lastovich et al.  |
| 6,673,081 | B1 | 1/2004  | Tavger et al.       | 7,318,828 | B1 | 1/2008  | Revivo            |
| 6,673,082 | B2 | 1/2004  | Mallett et al.      | 7,320,691 | B2 | 1/2008  | Pilcher et al.    |
| D486,915  | S  | 2/2004  | Warschewske et al.  | 7,320,801 | B2 | 1/2008  | Kelly             |
| 6,685,853 | B1 | 2/2004  | Angelopoulos et al. | 7,326,199 | B2 | 2/2008  | MacFarland et al. |
| 6,687,537 | B2 | 2/2004  | Bernabei            | 7,329,252 | B1 | 2/2008  | Yamazaki et al.   |
| 6,689,380 | B1 | 2/2004  | Marchitto et al.    | 7,354,423 | B2 | 4/2008  | Zelickson et al.  |
| 6,695,853 | B2 | 2/2004  | Karasiuk            | 7,364,565 | B2 | 4/2008  | Freeman           |
| 6,699,237 | B2 | 3/2004  | Weber et al.        | 7,367,981 | B2 | 5/2008  | Bernaz            |
| 6,712,805 | B2 | 3/2004  | Weimann             | 7,384,405 | B2 | 6/2008  | Rhoades           |
| 6,726,673 | B1 | 4/2004  | Zhang et al.        | 7,422,567 | B2 | 9/2008  | Lastovich et al.  |
| D490,561  | S  | 5/2004  | Angeletta           | 7,427,273 | B2 | 9/2008  | Mitsui            |
| 6,735,470 | B2 | 5/2004  | Henley et al.       | 7,440,798 | B2 | 10/2008 | Redding, Jr.      |
| 6,743,211 | B1 | 6/2004  | Prausnitz et al.    | 7,458,944 | B2 | 12/2008 | Liste et al.      |
| 6,743,215 | B2 | 6/2004  | Bernabei            | D584,151  | S  | 1/2009  | Murphy            |
| 6,764,493 | B1 | 7/2004  | Weber et al.        | 7,476,205 | B2 | 1/2009  | Erdmann           |
| 6,780,426 | B2 | 8/2004  | Zhang et al.        | 7,477,938 | B2 | 1/2009  | Sun et al.        |
| D496,101  | S  | 9/2004  | Davison             | 7,482,314 | B2 | 1/2009  | Grimes et al.     |
| 6,800,083 | B2 | 10/2004 | Hiblar et al.       | 7,485,125 | B2 | 2/2009  | Sjostrom          |
| 6,800,849 | B2 | 10/2004 | Staats              | 7,489,989 | B2 | 2/2009  | Sukhanov et al.   |
| D499,207  | S  | 11/2004 | Angeletta           | 7,494,503 | B2 | 2/2009  | McDaniel          |
| D499,841  | S  | 12/2004 | Angeletta           | 7,507,228 | B2 | 3/2009  | Sun et al.        |
| D502,288  | S  | 2/2005  | Longoria            | 7,572,238 | B2 | 8/2009  | Rhoades           |
| D502,289  | S  | 2/2005  | Longoria            | 7,582,067 | B2 | 9/2009  | Van Acker         |
| D502,569  | S  | 3/2005  | Longoria            | 7,597,900 | B2 | 10/2009 | Zimmer et al.     |
| 6,869,611 | B1 | 3/2005  | Kligman et al.      | 7,597,901 | B2 | 10/2009 | Clarot et al.     |
| 6,878,144 | B2 | 4/2005  | Altshuler et al.    | 7,607,972 | B2 | 10/2009 | Groman            |
| 6,887,260 | B1 | 5/2005  | McDaniel            | 7,658,742 | B2 | 2/2010  | Karasiuk          |
| 6,905,487 | B2 | 6/2005  | Zimmerman           | 7,678,120 | B2 | 3/2010  | Shadduck          |
| 6,911,031 | B2 | 6/2005  | Muldner             | 7,730,979 | B2 | 6/2010  | Kahrig            |
| 6,926,681 | B1 | 8/2005  | Ramey et al.        | 7,731,570 | B2 | 6/2010  | Groman            |
| 6,938,805 | B2 | 9/2005  | Brincat             | 7,740,651 | B2 | 6/2010  | Barak et al.      |
| 6,942,649 | B2 | 9/2005  | Ignon et al.        | 7,744,582 | B2 | 6/2010  | Sadowski et al.   |
| 6,960,206 | B2 | 11/2005 | Keane               | 7,749,260 | B2 | 7/2010  | Da Silva et al.   |
| 6,980,448 | B2 | 12/2005 | Foss et al.         | 7,758,537 | B1 | 7/2010  | Brunell et al.    |
| 7,001,355 | B2 | 2/2006  | Nunomura et al.     | 7,771,374 | B2 | 8/2010  | Slatkine          |
| 7,004,933 | B2 | 2/2006  | McDaniel            | 7,780,652 | B2 | 8/2010  | MacFarland et al. |
| D517,699  | S  | 3/2006  | Lansohn             | 7,789,886 | B2 | 9/2010  | Shadduck          |
| 7,031,805 | B2 | 4/2006  | Lee et al.          | D625,198  | S  | 10/2010 | Hall              |
| 7,044,938 | B2 | 5/2006  | La Bianco et al.    | 7,814,915 | B2 | 10/2010 | Davenport et al.  |
| 7,051,907 | B2 | 5/2006  | Brincat             | 7,837,695 | B2 | 11/2010 | Hart et al.       |
| 7,052,503 | B2 | 5/2006  | Bernabei            | 7,857,806 | B2 | 12/2010 | Karpowicz et al.  |
| D522,360  | S  | 6/2006  | Caserta et al.      | 7,862,564 | B2 | 1/2011  | Goble             |
| 7,062,317 | B2 | 6/2006  | Avrahami et al.     | 7,901,373 | B2 | 3/2011  | Tavger            |
| 7,069,073 | B2 | 6/2006  | Henley et al.       | 7,927,188 | B2 | 4/2011  | Groman            |
| 7,070,488 | B2 | 7/2006  | Suissa et al.       | 7,951,156 | B2 | 5/2011  | Karasiuk          |
| 7,083,580 | B2 | 8/2006  | Bernabei            | D639,164  | S  | 6/2011  | Walsh             |
| 7,087,036 | B2 | 8/2006  | Busby et al.        | 7,981,111 | B2 | 7/2011  | Grove et al.      |
| 7,087,063 | B2 | 8/2006  | Carson et al.       | 7,981,112 | B1 | 7/2011  | Neev              |
| 7,094,252 | B2 | 8/2006  | Koop                | 7,993,333 | B2 | 8/2011  | Oral et al.       |
| 7,108,689 | B2 | 9/2006  | Eckhouse et al.     | 8,025,669 | B1 | 9/2011  | David et al.      |
| 7,115,275 | B2 | 10/2006 | Clarot et al.       | RE42,960  | E  | 11/2011 | Waldron           |
| 7,118,563 | B2 | 10/2006 | Weckwerth et al.    | 8,048,064 | B2 | 11/2011 | Hwang et al.      |
| 7,122,029 | B2 | 10/2006 | Koop et al.         | 8,048,089 | B2 | 11/2011 | Ignon et al.      |
| 7,135,011 | B2 | 11/2006 | Powers et al.       | 8,066,716 | B2 | 11/2011 | Shadduck          |
|           |    |         |                     | 8,088,085 | B2 | 1/2012  | Thiebaut et al.   |
|           |    |         |                     | 8,105,295 | B2 | 1/2012  | Blott et al.      |
|           |    |         |                     | 8,128,638 | B2 | 3/2012  | Karasluk et al.   |
|           |    |         |                     | 8,135,475 | B2 | 3/2012  | Kreindel et al.   |

(56)

## References Cited

## U.S. PATENT DOCUMENTS

|              |         |                            |                |         |                         |
|--------------|---------|----------------------------|----------------|---------|-------------------------|
| 8,182,473 B2 | 5/2012  | Altshuler et al.           | 9,227,082 B2   | 1/2016  | McDaniel                |
| D664,254 S   | 7/2012  | Yokoyama et al.            | 9,233,207 B2   | 1/2016  | Polyakov et al.         |
| 8,221,437 B2 | 7/2012  | Waldron et al.             | 9,271,755 B2   | 3/2016  | Luzon et al.            |
| 8,226,663 B2 | 7/2012  | Remsburg et al.            | 9,278,230 B2   | 3/2016  | Levin et al.            |
| 8,231,292 B2 | 7/2012  | Rabe et al.                | 9,283,037 B2   | 3/2016  | Bragagna et al.         |
| 8,236,008 B2 | 8/2012  | Boone, III et al.          | 9,314,302 B2   | 4/2016  | Douga                   |
| 8,236,036 B1 | 8/2012  | Frost                      | 9,351,792 B2   | 5/2016  | Manstein et al.         |
| 8,241,094 B2 | 8/2012  | Groman                     | 9,351,794 B2   | 5/2016  | Suckewer et al.         |
| 8,273,080 B2 | 9/2012  | Mehta                      | 9,375,281 B2   | 6/2016  | Moench et al.           |
| 8,276,592 B2 | 10/2012 | Davenport et al.           | 9,421,260 B2   | 8/2016  | Harris et al.           |
| 8,277,287 B2 | 10/2012 | Hart                       | 9,421,261 B2   | 8/2016  | Harris et al.           |
| 8,282,630 B2 | 10/2012 | Neev                       | D765,512 S     | 9/2016  | Joulia                  |
| 8,313,480 B2 | 11/2012 | Neev                       | 9,439,964 B2   | 9/2016  | Harris et al.           |
| 8,317,781 B2 | 11/2012 | Owens et al.               | 9,440,093 B2   | 9/2016  | Homer                   |
| 8,323,253 B2 | 12/2012 | Hantash et al.             | 9,452,013 B2   | 9/2016  | Manstein                |
| 8,337,513 B2 | 12/2012 | Shaddock                   | 9,468,464 B2   | 10/2016 | Shaddock                |
| 8,343,116 B2 | 1/2013  | Ignon et al.               | 9,474,886 B2   | 10/2016 | Ignon et al.            |
| 8,360,826 B2 | 1/2013  | Groman                     | D772,481 S     | 11/2016 | Paquet                  |
| D676,764 S   | 2/2013  | Moore et al.               | 9,480,836 B2   | 11/2016 | Na                      |
| D678,783 S   | 3/2013  | Wilcox et al.              | 9,486,615 B2   | 11/2016 | Ignon et al.            |
| 8,398,621 B2 | 3/2013  | Beerwerth et al.           | 9,498,610 B2   | 11/2016 | Gnon et al.             |
| D680,437 S   | 4/2013  | Bartolo et al.             | 9,517,085 B2   | 12/2016 | Karasluk                |
| 8,430,104 B2 | 4/2013  | Hennings et al.            | 9,522,287 B2   | 12/2016 | Owens et al.            |
| 8,435,234 B2 | 5/2013  | Chan et al.                | 9,550,052 B2 * | 1/2017  | Ignon ..... A61M 35/003 |
| 8,475,507 B2 | 7/2013  | Dewey et al.               | 9,566,088 B2   | 2/2017  | Ignon et al.            |
| 8,478,396 B2 | 7/2013  | Tsao et al.                | 9,566,454 B2   | 2/2017  | Barthe et al.           |
| 8,480,721 B2 | 7/2013  | Owens et al.               | 9,572,880 B2   | 2/2017  | Harris et al.           |
| 8,496,654 B2 | 7/2013  | Adanny et al.              | 9,597,527 B2   | 3/2017  | Buchholz et al.         |
| 8,496,695 B2 | 7/2013  | Kang et al.                | D782,881 S     | 4/2017  | Seiders et al.          |
| 8,535,299 B2 | 9/2013  | Giovannoli                 | D787,054 S     | 5/2017  | Rini et al.             |
| 8,545,419 B2 | 10/2013 | Kim                        | 9,636,521 B2   | 5/2017  | Isserow et al.          |
| 8,545,489 B2 | 10/2013 | Giovannoli                 | 9,636,522 B2   | 5/2017  | Oversluizen et al.      |
| 8,551,104 B2 | 10/2013 | Weckwerth et al.           | 9,642,997 B2   | 5/2017  | Ignon et al.            |
| 8,562,626 B2 | 10/2013 | Sabir et al.               | 9,662,482 B2   | 5/2017  | Ignon et al.            |
| 8,573,874 B2 | 11/2013 | Neuner                     | 9,669,233 B2   | 6/2017  | Quisenberry et al.      |
| 8,579,916 B2 | 11/2013 | Cheney                     | 9,675,817 B2   | 6/2017  | Isserow et al.          |
| 8,597,284 B2 | 12/2013 | Castro                     | 9,694,199 B2   | 7/2017  | Duquet et al.           |
| D697,404 S   | 1/2014  | Johnson et al.             | 9,700,684 B2   | 7/2017  | Vlodaver et al.         |
| 8,632,378 B2 | 1/2014  | Groman                     | 9,731,053 B2   | 8/2017  | Alal                    |
| 8,656,931 B2 | 2/2014  | Davenport et al.           | 9,744,315 B1   | 8/2017  | Levi                    |
| 8,668,552 B2 | 3/2014  | Groman                     | 9,775,645 B2   | 10/2017 | Boone, III              |
| 8,679,039 B2 | 3/2014  | Tieu et al.                | 9,775,646 B2   | 10/2017 | Shaddock                |
| 8,700,176 B2 | 4/2014  | Azar et al.                | 9,775,976 B2   | 10/2017 | Greze                   |
| 8,702,691 B2 | 4/2014  | Weber et al.               | 9,814,485 B2   | 11/2017 | Pratt et al.            |
| 8,702,771 B1 | 4/2014  | Frost                      | 9,814,647 B2   | 11/2017 | Ajiki                   |
| 8,721,662 B2 | 5/2014  | Karasiuk                   | 9,814,868 B2   | 11/2017 | Ignon et al.            |
| 8,728,064 B2 | 5/2014  | Schomacker et al.          | 9,814,906 B2   | 11/2017 | McDaniel                |
| 8,740,917 B2 | 6/2014  | Pilcher et al.             | 9,833,261 B2   | 12/2017 | Boone, III et al.       |
| D709,617 S   | 7/2014  | Iliesco de Grimaldi et al. | 9,861,442 B2   | 1/2018  | Tankovich et al.        |
| 8,814,836 B2 | 8/2014  | Ignon et al.               | D811,225 S     | 2/2018  | Newson                  |
| 8,818,500 B2 | 8/2014  | Duquet et al.              | D811,381 S     | 2/2018  | Morohoshi et al.        |
| 8,821,940 B2 | 9/2014  | Harris et al.              | 9,918,727 B1   | 3/2018  | Boone, III et al.       |
| 8,834,933 B2 | 9/2014  | Harris et al.              | 9,949,552 B2   | 4/2018  | Rabe et al.             |
| 8,858,570 B2 | 10/2014 | Chang                      | 9,950,147 B2   | 4/2018  | Mehta                   |
| 8,939,669 B2 | 1/2015  | Le et al.                  | 9,955,769 B2   | 5/2018  | Rabe et al.             |
| D722,172 S   | 2/2015  | Amemiya et al.             | 9,962,220 B2   | 5/2018  | Domankevitz             |
| 8,945,104 B2 | 2/2015  | Boone, III et al.          | 9,968,800 B2   | 5/2018  | Anderson et al.         |
| 8,945,109 B2 | 2/2015  | Mehta                      | 10,004,919 B2  | 6/2018  | Lemmens et al.          |
| 8,974,442 B1 | 3/2015  | Boss, Jr.                  | D822,845 S     | 7/2018  | Shimobayashi et al.     |
| 9,017,391 B2 | 4/2015  | McDaniel                   | 10,010,445 B2  | 7/2018  | Isserow et al.          |
| 9,017,392 B2 | 4/2015  | Owens et al.               | 10,022,289 B2  | 7/2018  | Ajiki et al.            |
| 9,044,582 B2 | 6/2015  | Chang et al.               | 10,035,007 B2  | 7/2018  | Ignon et al.            |
| 9,050,133 B1 | 6/2015  | Boone, III et al.          | D825,763 S     | 8/2018  | Lim et al.              |
| 9,050,156 B2 | 6/2015  | Groman                     | 10,052,467 B2  | 8/2018  | Bansal et al.           |
| 9,056,193 B2 | 6/2015  | Ignon et al.               | 10,076,354 B2  | 9/2018  | Knowlton                |
| D734,154 S   | 7/2015  | Johnson et al.             | 10,076,646 B2  | 9/2018  | Casasanta, III et al.   |
| 9,072,521 B2 | 7/2015  | Levi et al.                | 10,080,581 B2  | 9/2018  | Knowlton                |
| 9,072,533 B2 | 7/2015  | Liu et al.                 | 10,092,478 B1  | 10/2018 | Amit                    |
| 9,072,892 B2 | 7/2015  | Owens et al.               | 10,105,191 B2  | 10/2018 | Blanco et al.           |
| 9,084,587 B2 | 7/2015  | Eckhouse et al.            | D833,283 S     | 11/2018 | Rock                    |
| 9,149,322 B2 | 10/2015 | Knowlton                   | 10,130,390 B1  | 11/2018 | Hart et al.             |
| D743,269 S   | 11/2015 | Pape                       | 10,130,827 B2  | 11/2018 | Buchholz et al.         |
| D743,558 S   | 11/2015 | Kim et al.                 | D836,781 S     | 12/2018 | Meurer et al.           |
| 9,186,490 B2 | 11/2015 | Chang et al.               | 10,149,969 B2  | 12/2018 | Greze et al.            |
| 9,227,044 B2 | 1/2016  | Bansal et al.              | 10,149,984 B2  | 12/2018 | Modi et al.             |
|              |         |                            | 10,172,644 B2  | 1/2019  | Ignon et al.            |
|              |         |                            | 10,179,229 B2  | 1/2019  | Ignon et al.            |
|              |         |                            | 10,183,183 B2  | 1/2019  | Burdette                |
|              |         |                            | 10,188,193 B2  | 1/2019  | Rabe et al.             |

(56)

## References Cited

## U.S. PATENT DOCUMENTS

|               |         |                    |                   |         |                                    |
|---------------|---------|--------------------|-------------------|---------|------------------------------------|
| 10,206,743 B2 | 2/2019  | Tankovich et al.   | D928,977 S        | 8/2021  | Dijkstra                           |
| 10,207,034 B2 | 2/2019  | Collins            | 11,083,515 B2     | 8/2021  | Slatkine et al.                    |
| 10,220,122 B2 | 3/2019  | Clark, III et al.  | 11,123,039 B2     | 9/2021  | Barthe et al.                      |
| 10,238,812 B2 | 3/2019  | Ignon              | 11,141,761 B2     | 10/2021 | Connelly et al.                    |
| 10,238,849 B2 | 3/2019  | Britva et al.      | 11,154,723 B2     | 10/2021 | Lee                                |
| 10,251,675 B2 | 4/2019  | Ignon et al.       | 11,172,978 B2     | 11/2021 | Wooten et al.                      |
| 10,252,044 B2 | 4/2019  | Bock               | 11,202,657 B2     | 12/2021 | Ignon et al.                       |
| 10,271,900 B2 | 4/2019  | Marchitto et al.   | 11,213,321 B2     | 1/2022  | Ignon et al.                       |
| 10,272,258 B2 | 4/2019  | Quisenberry et al. | 11,224,728 B2     | 1/2022  | Ignon et al.                       |
| D851,759 S    | 6/2019  | Jones et al.       | 11,241,357 B2     | 2/2022  | Ignon et al.                       |
| 10,307,330 B1 | 6/2019  | Sedic              | 11,247,039 B2     | 2/2022  | Schwarz                            |
| 10,308,378 B2 | 6/2019  | Goodwin et al.     | 11,278,101 B2     | 3/2022  | Jeannin et al.                     |
| 10,314,378 B2 | 6/2019  | Rabe et al.        | 11,291,474 B2     | 4/2022  | Nicolas et al.                     |
| 10,321,948 B2 | 6/2019  | Knowlton           | 11,291,498 B2     | 4/2022  | Slatkine et al.                    |
| 10,328,277 B2 | 6/2019  | Modi et al.        | 11,311,721 B2     | 4/2022  | Ebbers et al.                      |
| D852,962 S    | 7/2019  | Chang              | 11,337,745 B2     | 5/2022  | Kim                                |
| 10,335,191 B2 | 7/2019  | Knowlton           | 11,337,755 B2     | 5/2022  | Hancock et al.                     |
| 10,357,641 B2 | 7/2019  | Ignon et al.       | 11,351,063 B2     | 6/2022  | Locke et al.                       |
| 10,357,642 B2 | 7/2019  | Ignon et al.       | 11,419,678 B2     | 8/2022  | Deem et al.                        |
| 10,334,933 B2 | 8/2019  | Rosario et al.     | 11,446,477 B2 *   | 9/2022  | Ignon ..... A61B 17/54             |
| 10,369,073 B2 | 8/2019  | Rosario et al.     | 11,452,852 B2     | 9/2022  | Quan et al.                        |
| 10,413,359 B2 | 9/2019  | Felsenstein et al. | 11,497,553 B2     | 11/2022 | Reinhard et al.                    |
| D861,913 S    | 10/2019 | Stamm et al.       | 11,504,148 B2     | 11/2022 | Friend                             |
| 10,456,197 B2 | 10/2019 | Felsenstein et al. | 11,517,350 B2     | 12/2022 | Ignon et al.                       |
| 10,456,321 B2 | 10/2019 | Shaddock           | 11,540,882 B2     | 1/2023  | Masotti et al.                     |
| 10,456,567 B2 | 10/2019 | Streeter           | 11,547,840 B2     | 1/2023  | Ignon et al.                       |
| D867,587 S    | 11/2019 | Holtz              | 11,590,345 B2     | 2/2023  | Danitz et al.                      |
| 10,463,429 B2 | 11/2019 | Deem et al.        | 11,602,629 B2     | 3/2023  | Schwarz et al.                     |
| 10,471,274 B2 | 11/2019 | Liu et al.         | 11,612,726 B2     | 3/2023  | Ignon et al.                       |
| 10,485,983 B1 | 11/2019 | Boone, III et al.  | 11,717,326 B2     | 8/2023  | Ignon et al.                       |
| D868,981 S    | 12/2019 | Salamon et al.     | 11,744,999 B2     | 9/2023  | Ignon et al.                       |
| D873,430 S    | 1/2020  | Accolla            | 2001/0023351 A1   | 9/2001  | Eilers                             |
| D873,481 S    | 1/2020  | Larkin             | 2001/0049511 A1 * | 12/2001 | Coleman ..... A61H 9/00<br>604/290 |
| 10,524,835 B2 | 1/2020  | Shaddock et al.    | 2002/0016601 A1   | 2/2002  | Shaddock                           |
| 10,537,304 B2 | 1/2020  | Barthe et al.      | 2002/0040199 A1   | 4/2002  | Klopotek                           |
| 10,537,640 B2 | 1/2020  | Harris et al.      | 2002/0041891 A1   | 4/2002  | Cheski                             |
| 10,556,096 B2 | 2/2020  | Ignon et al.       | 2002/0058952 A1   | 5/2002  | Weber et al.                       |
| 10,556,097 B2 | 2/2020  | Ignon et al.       | 2002/0099356 A1   | 7/2002  | Unger et al.                       |
| 10,583,037 B2 | 3/2020  | Isserow et al.     | 2002/0107527 A1   | 8/2002  | Burres                             |
| D886,370 S    | 6/2020  | Soutelo Gomes      | 2002/0128663 A1   | 9/2002  | Mercier et al.                     |
| D886,372 S    | 6/2020  | Weinrich           | 2002/0133110 A1   | 9/2002  | Citow                              |
| D887,571 S    | 6/2020  | Liu                | 2002/0133176 A1   | 9/2002  | Parkin et al.                      |
| 10,667,985 B2 | 6/2020  | Decaux et al.      | 2002/0151826 A1   | 10/2002 | Ramey et al.                       |
| 10,675,481 B1 | 6/2020  | Tankovich          | 2002/0162863 A1   | 11/2002 | Brincat                            |
| 10,688,290 B1 | 6/2020  | Yuval              | 2002/0188261 A1   | 12/2002 | Hruska                             |
| 10,702,328 B2 | 7/2020  | Slatkine et al.    | 2002/0198488 A1   | 12/2002 | Yao                                |
| 10,716,924 B2 | 7/2020  | Knowlton           | 2003/0012415 A1   | 1/2003  | Cossel                             |
| D893,024 S    | 8/2020  | Whiteside          | 2003/0018252 A1 * | 1/2003  | Duchon ..... A61B 6/504<br>600/432 |
| 10,736,653 B2 | 8/2020  | Knowlton           | 2003/0060834 A1   | 3/2003  | Muldner                            |
| 10,737,080 B2 | 8/2020  | Patterson          | 2003/0093040 A1   | 5/2003  | Miksza et al.                      |
| 10,758,261 B2 | 9/2020  | Richardson         | 2003/0093089 A1   | 5/2003  | Greenberg                          |
| 10,772,658 B2 | 9/2020  | Knowlton           | 2003/0097139 A1   | 5/2003  | Karasiuk                           |
| 10,792,382 B2 | 10/2020 | Rafko              | 2003/0135388 A1   | 7/2003  | Martucci et al.                    |
| 10,799,285 B2 | 10/2020 | Mulholland         | 2003/0187462 A1   | 10/2003 | Chang                              |
| 10,799,430 B2 | 10/2020 | Danto              | 2003/0208159 A1   | 11/2003 | Ignon et al.                       |
| 10,813,694 B2 | 10/2020 | Johnson et al.     | 2003/0212127 A1   | 11/2003 | Glassman et al.                    |
| 10,835,287 B2 | 11/2020 | Shaddock et al.    | 2003/0212415 A1   | 11/2003 | Karasiuk                           |
| 10,835,726 B2 | 11/2020 | Redding, Jr.       | 2004/0005349 A1   | 1/2004  | Neev                               |
| 10,850,095 B2 | 12/2020 | Ebbers et al.      | 2004/0010222 A1   | 1/2004  | Nunomura et al.                    |
| 10,856,900 B2 | 12/2020 | Knowlton           | 2004/0010269 A1   | 1/2004  | Grimes et al.                      |
| 10,860,026 B2 | 12/2020 | Nguyen et al.      | 2004/0015139 A1   | 1/2004  | La Bianco                          |
| 10,874,579 B1 | 12/2020 | Rembert            | 2004/0087972 A1   | 5/2004  | Mulholland et al.                  |
| D908,282 S    | 1/2021  | Kim                | 2004/0092895 A1   | 5/2004  | Harmon                             |
| 10,893,907 B2 | 1/2021  | Kim                | 2004/0092959 A1   | 5/2004  | Bernaz                             |
| 10,912,428 B2 | 2/2021  | Daffer             | 2004/0097967 A1   | 5/2004  | Ignon                              |
| 10,918,190 B2 | 2/2021  | Laudati            | 2004/0122447 A1   | 6/2004  | Harmon et al.                      |
| 10,946,191 B2 | 3/2021  | Cazares Delgadillo | 2004/0127914 A1   | 7/2004  | Chung                              |
| 10,952,811 B2 | 3/2021  | Blanco et al.      | 2004/0138680 A1   | 7/2004  | Twitchell et al.                   |
| 10,952,907 B1 | 3/2021  | Carver             | 2004/0162565 A1   | 8/2004  | Carson et al.                      |
| D917,290 S    | 4/2021  | Bravman et al.     | 2004/0166172 A1   | 8/2004  | Rosati et al.                      |
| 10,980,592 B2 | 4/2021  | Horton et al.      | 2004/0176823 A1   | 9/2004  | Island et al.                      |
| 10,993,743 B2 | 5/2021  | Ignon et al.       | 2004/0210280 A1   | 10/2004 | Liedtke                            |
| 11,020,577 B2 | 6/2021  | Ignon et al.       | 2004/0219179 A1   | 11/2004 | McDaniel                           |
| 11,045,661 B2 | 6/2021  | Oversluizen et al. | 2004/0229295 A1   | 11/2004 | Marchitto et al.                   |
| D927,008 S    | 8/2021  | Rappaport          | 2004/0236291 A1   | 11/2004 | Zelickson et al.                   |
|               |         |                    | 2004/0236375 A1   | 11/2004 | Redding, Jr.                       |
|               |         |                    | 2004/0243149 A1   | 12/2004 | Lee, Jr.                           |

(56)

## References Cited

## U.S. PATENT DOCUMENTS

|              |    |         |                     |              |    |         |                        |
|--------------|----|---------|---------------------|--------------|----|---------|------------------------|
| 2004/0254587 | A1 | 12/2004 | Park                | 2008/0154161 | A1 | 6/2008  | Abbott                 |
| 2004/0267285 | A1 | 12/2004 | Chang               | 2008/0154183 | A1 | 6/2008  | Baker et al.           |
| 2005/0015077 | A1 | 1/2005  | Kuklin et al.       | 2008/0161799 | A1 | 7/2008  | Stangenes et al.       |
| 2005/0037034 | A1 | 2/2005  | Rhoades             | 2008/0188840 | A1 | 8/2008  | Johnson et al.         |
| 2005/0038377 | A1 | 2/2005  | Redding, Jr.        | 2008/0193493 | A1 | 8/2008  | Rhoades                |
| 2005/0038448 | A1 | 2/2005  | Chung               | 2008/0200861 | A1 | 8/2008  | Shalev et al.          |
| 2005/0059940 | A1 | 3/2005  | Weber et al.        | 2008/0200863 | A1 | 8/2008  | Chomas et al.          |
| 2005/0065461 | A1 | 3/2005  | Redding, Jr.        | 2008/0208146 | A1 | 8/2008  | Brandwein et al.       |
| 2005/0070977 | A1 | 3/2005  | Molina              | 2008/0208179 | A1 | 8/2008  | Chan et al.            |
| 2005/0075599 | A1 | 4/2005  | Redding, Jr.        | 2008/0214987 | A1 | 9/2008  | Xu                     |
| 2005/0080465 | A1 | 4/2005  | Zelickson et al.    | 2008/0215068 | A1 | 9/2008  | Hart et al.            |
| 2005/0084509 | A1 | 4/2005  | Bernstein           | 2008/0221548 | A1 | 9/2008  | Danenberg et al.       |
| 2005/0148958 | A1 | 7/2005  | Rucinski            | 2008/0234626 | A1 | 9/2008  | Chelak                 |
| 2005/0154333 | A1 | 7/2005  | Mulholland et al.   | 2008/0243039 | A1 | 10/2008 | Rhoades                |
| 2005/0203111 | A1 | 9/2005  | David               | 2008/0287864 | A1 | 11/2008 | Rosenberg              |
| 2005/0203593 | A1 | 9/2005  | Shanks et al.       | 2008/0300529 | A1 | 12/2008 | Reinstein              |
| 2005/0209611 | A1 | 9/2005  | Greenberg           | 2008/0300552 | A1 | 12/2008 | Cichocki et al.        |
| 2005/0245180 | A1 | 11/2005 | Suissa et al.       | 2009/0048557 | A1 | 2/2009  | Yeshurun et al.        |
| 2005/0283176 | A1 | 12/2005 | Law                 | 2009/0053390 | A1 | 2/2009  | Sakou et al.           |
| 2006/0002960 | A1 | 1/2006  | Zoetewij et al.     | 2009/0062815 | A1 | 3/2009  | Karasiuk et al.        |
| 2006/0015059 | A1 | 1/2006  | Redding, Jr.        | 2009/0099091 | A1 | 4/2009  | Hantash                |
| 2006/0058714 | A1 | 3/2006  | Rhoades             | 2009/0099093 | A1 | 4/2009  | Hantash                |
| 2006/0100567 | A1 | 5/2006  | Marchitto et al.    | 2009/0118684 | A1 | 5/2009  | Da Silva et al.        |
| 2006/0116674 | A1 | 6/2006  | Goble et al.        | 2009/0124985 | A1 | 5/2009  | Hasenoechl et al.      |
| 2006/0161178 | A1 | 7/2006  | Lee                 | 2009/0132012 | A1 | 5/2009  | Shanks                 |
| 2006/0184071 | A1 | 8/2006  | Klopotek            | 2009/0138026 | A1 | 5/2009  | Wu                     |
| 2006/0189964 | A1 | 8/2006  | Anderson            | 2009/0171191 | A1 | 7/2009  | Patrick et al.         |
| 2006/0191562 | A1 | 8/2006  | Numomura            | 2009/0171194 | A1 | 7/2009  | Patrick et al.         |
| 2006/0200099 | A1 | 9/2006  | La Bianco et al.    | 2009/0222023 | A1 | 9/2009  | Boone, III et al.      |
| 2006/0200213 | A1 | 9/2006  | McDaniel            | 2009/0254014 | A1 | 10/2009 | Son                    |
| 2006/0212025 | A1 | 9/2006  | McDaniel            | 2009/0299237 | A1 | 12/2009 | Rhoades                |
| 2006/0212029 | A1 | 9/2006  | Villacampa et al.   | 2010/0023003 | A1 | 1/2010  | Mulholland             |
| 2006/0222445 | A1 | 10/2006 | Chuang              | 2010/0045427 | A1 | 2/2010  | Boone, III et al.      |
| 2006/0235371 | A1 | 10/2006 | Wakamatsu et al.    | 2010/0048980 | A1 | 2/2010  | De Jong et al.         |
| 2006/0253078 | A1 | 11/2006 | Wu et al.           | 2010/0049177 | A1 | 2/2010  | Boone, III et al.      |
| 2006/0253079 | A1 | 11/2006 | McDonough et al.    | 2010/0049210 | A1 | 2/2010  | Boone, III et al.      |
| 2006/0253125 | A1 | 11/2006 | Ignon               | 2010/0056847 | A1 | 3/2010  | De Jong et al.         |
| 2006/0264893 | A1 | 11/2006 | Sage, Jr. et al.    | 2010/0063565 | A1 | 3/2010  | Beerwerth et al.       |
| 2006/0264926 | A1 | 11/2006 | Kochamba            | 2010/0217357 | A1 | 8/2010  | Da Silva               |
| 2006/0269580 | A1 | 11/2006 | Cole et al.         | 2010/0305495 | A1 | 12/2010 | Anderson et al.        |
| 2006/0278661 | A1 | 12/2006 | Cooper et al.       | 2011/0054490 | A1 | 3/2011  | Hart                   |
| 2007/0005078 | A1 | 1/2007  | Hart et al.         | 2011/0060270 | A1 | 3/2011  | Eppstein               |
| 2007/0020321 | A1 | 1/2007  | Redding et al.      | 2011/0066162 | A1 | 3/2011  | Cohen                  |
| 2007/0043382 | A1 | 2/2007  | Cheney              | 2011/0067761 | A1 | 6/2011  | King                   |
| 2007/0049901 | A1 | 3/2007  | Wu et al.           | 2011/0190726 | A1 | 8/2011  | Hantash et al.         |
| 2007/0065515 | A1 | 3/2007  | Key                 | 2011/0251523 | A1 | 10/2011 | Kim                    |
| 2007/0073327 | A1 | 3/2007  | Giovannoli          | 2011/0264028 | A1 | 10/2011 | Ramdas et al.          |
| 2007/0078290 | A1 | 4/2007  | Esenaliev           | 2011/0270137 | A1 | 11/2011 | Goren et al.           |
| 2007/0088245 | A1 | 4/2007  | Babaev et al.       | 2011/0270364 | A1 | 11/2011 | Kreindel et al.        |
| 2007/0088371 | A1 | 4/2007  | Karasiuk            | 2011/0295273 | A1 | 12/2011 | Waldron et al.         |
| 2007/0093694 | A1 | 4/2007  | Fassuliotis et al.  | 2012/0041338 | A1 | 2/2012  | Chickering, III et al. |
| 2007/0123808 | A1 | 5/2007  | Rhoades             | 2012/0041523 | A1 | 2/2012  | Solomon et al.         |
| 2007/0139630 | A1 | 6/2007  | Kleman et al.       | 2012/0109041 | A1 | 5/2012  | Munz                   |
| 2007/0149991 | A1 | 6/2007  | Mulholland          | 2012/0109043 | A1 | 5/2012  | Zhou et al.            |
| 2007/0154502 | A1 | 7/2007  | Hattendorf et al.   | 2012/0136374 | A1 | 5/2012  | Karasiuk               |
| 2007/0156124 | A1 | 7/2007  | Ignon et al.        | 2012/0171636 | A1 | 7/2012  | Groman                 |
| 2007/0178121 | A1 | 8/2007  | First et al.        | 2012/0259252 | A1 | 10/2012 | Thorn-Leeson et al.    |
| 2007/0198031 | A1 | 8/2007  | Kellogg             | 2012/0289885 | A1 | 11/2012 | Cottrell               |
| 2007/0232987 | A1 | 10/2007 | Diaz et al.         | 2012/0302929 | A1 | 11/2012 | Tkachenko              |
| 2007/0239079 | A1 | 10/2007 | Manstein et al.     | 2013/0004230 | A1 | 1/2013  | Kirk, III et al.       |
| 2007/0239173 | A1 | 10/2007 | Khalaj              | 2013/0018317 | A1 | 1/2013  | Bobroff et al.         |
| 2007/0255355 | A1 | 11/2007 | Altshuler et al.    | 2013/0066336 | A1 | 3/2013  | Boone, III et al.      |
| 2007/0264625 | A1 | 11/2007 | DeBenedictis et al. | 2013/0085421 | A1 | 4/2013  | Gillespie et al.       |
| 2007/0270738 | A1 | 11/2007 | Wu et al.           | 2013/0096546 | A1 | 4/2013  | Mirkov et al.          |
| 2008/0009802 | A1 | 1/2008  | Lambino et al.      | 2013/0096577 | A1 | 4/2013  | Shadduck               |
| 2008/0015555 | A1 | 1/2008  | Manstein et al.     | 2013/0144207 | A1 | 6/2013  | Gonon                  |
| 2008/0027328 | A1 | 1/2008  | Klopotek et al.     | 2013/0144280 | A1 | 6/2013  | Eckhouse et al.        |
| 2008/0027518 | A1 | 1/2008  | Island et al.       | 2013/0158547 | A1 | 6/2013  | David                  |
| 2008/0091126 | A1 | 4/2008  | Greenburg           | 2013/0204238 | A1 | 8/2013  | Lederman et al.        |
| 2008/0091179 | A1 | 4/2008  | Durkin et al.       | 2013/0226075 | A1 | 8/2013  | Hennings et al.        |
| 2008/0103563 | A1 | 5/2008  | Powell              | 2013/0226269 | A1 | 8/2013  | Eckhouse et al.        |
| 2008/0119781 | A1 | 5/2008  | King                | 2013/0261534 | A1 | 10/2013 | Niezgoda et al.        |
| 2008/0132914 | A1 | 6/2008  | Bossard et al.      | 2013/0268032 | A1 | 10/2013 | Neev                   |
| 2008/0139974 | A1 | 6/2008  | Da Silva            | 2013/0310906 | A1 | 11/2013 | Neev                   |
| 2008/0146970 | A1 | 6/2008  | Litman et al.       | 2013/0317314 | A1 | 11/2013 | Lampson                |
|              |    |         |                     | 2013/0345616 | A1 | 12/2013 | Chang                  |
|              |    |         |                     | 2014/0031801 | A1 | 1/2014  | Giovannoli             |
|              |    |         |                     | 2014/0079686 | A1 | 3/2014  | Barman et al.          |
|              |    |         |                     | 2014/0081251 | A1 | 3/2014  | Giovannoli             |

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2014/0094718 A1 4/2014 Feldman  
 2014/0114234 A1 4/2014 Redding, Jr.  
 2014/0135798 A1 5/2014 David  
 2014/0234004 A1 8/2014 Thorpe et al.  
 2014/0243589 A1 8/2014 Rowan  
 2014/0316492 A1 10/2014 Min et al.  
 2014/0378887 A1 12/2014 Chang et al.  
 2015/0039060 A1 2/2015 Paulussen et al.  
 2015/0141877 A1 5/2015 Feldman  
 2015/0157496 A1 6/2015 Horton et al.  
 2015/0202007 A1 7/2015 Mainstein et al.  
 2015/0272623 A1 10/2015 Ignon et al.  
 2015/0313993 A1 11/2015 Bock  
 2015/0351868 A1 12/2015 Groman  
 2016/0015962 A1 1/2016 Maragheh et al.  
 2016/0018100 A1 1/2016 Batt et al.  
 2016/0175609 A1 6/2016 Dye et al.  
 2016/0220849 A1 8/2016 Knowlton  
 2016/0235257 A1 8/2016 Daffer  
 2016/0250415 A1 9/2016 Yagi et al.  
 2016/0270850 A1 9/2016 Manstein et al.  
 2016/0270851 A1 9/2016 Moench et al.  
 2016/0287333 A1 10/2016 Morrison  
 2016/0324578 A1 11/2016 Manstein et al.  
 2017/0043150 A1 2/2017 Kim  
 2017/0065829 A1 3/2017 Ku  
 2017/0106206 A1 4/2017 Seckel  
 2017/0128319 A1 5/2017 Decaux et al.  
 2017/0157419 A1 6/2017 Jeong  
 2017/0196759 A1 7/2017 Palomaki et al.  
 2017/0209894 A1 7/2017 Sporrer  
 2017/0252105 A1 9/2017 Deem et al.  
 2017/0291007 A1 10/2017 Dubey et al.  
 2017/0340356 A1 11/2017 Presser et al.  
 2017/0343308 A1 11/2017 Wojciechowski, III et al.  
 2018/0008500 A1 1/2018 Anderson et al.  
 2018/0140329 A1 5/2018 Beijens et al.  
 2018/0185675 A1 7/2018 Kern et al.  
 2018/0310979 A1 11/2018 Peled et al.  
 2018/0318568 A1 11/2018 Ignon et al.  
 2018/0326191 A1 11/2018 Bansal et al.  
 2019/0009110 A1 1/2019 Gross et al.  
 2019/0009111 A1 1/2019 Myhr et al.  
 2019/0070069 A1 3/2019 Gertner et al.  
 2019/0076193 A1 3/2019 Clementi et al.  
 2019/0083161 A1 3/2019 Harle et al.  
 2019/0143089 A1 5/2019 Ignon et al.  
 2019/0151637 A1 5/2019 Groop et al.  
 2019/0168016 A1 6/2019 Anderson et al.  
 2019/0183562 A1 6/2019 Widgerow  
 2019/0209859 A1 7/2019 Quisenberry et al.  
 2019/0223914 A1 7/2019 Ignon et al.  
 2019/0224501 A1 7/2019 Burdette  
 2019/0239939 A1 8/2019 Boll et al.  
 2019/0240110 A1 8/2019 Sedic  
 2019/0240502 A1 8/2019 Anderson et al.  
 2019/0257320 A1 8/2019 Petit et al.  
 2019/0274759 A1 9/2019 Royon et al.  
 2019/0275320 A1 9/2019 Kim et al.  
 2019/0366067 A1 12/2019 Ginggen et al.  
 2020/0009007 A1 1/2020 Shaddock  
 2020/0016342 A1 1/2020 Ignon  
 2020/0030627 A1 1/2020 Eltorai et al.  
 2020/0101312 A1 4/2020 Pal et al.  
 2020/0114116 A1 4/2020 Dubey et al.  
 2020/0121354 A1 4/2020 Ginggen et al.  
 2020/0171288 A1 6/2020 Ignon et al.  
 2020/0171289 A1 6/2020 Ignon et al.  
 2020/0179220 A1 6/2020 Jablow  
 2020/0206072 A1 7/2020 Capelli et al.  
 2020/0254273 A1 8/2020 Jafari et al.  
 2020/0275945 A1 9/2020 Knowlton  
 2020/0288843 A1 9/2020 Verheem  
 2020/0289161 A1 9/2020 Scooros  
 2020/0306555 A1 10/2020 Ebbesson

2020/0316270 A1 10/2020 Dijkstra et al.  
 2020/0330754 A1 10/2020 Kim et al.  
 2020/0338586 A1 10/2020 Park  
 2020/0367961 A1 11/2020 Podmore et al.  
 2020/0390468 A1 12/2020 Alexander  
 2021/0001148 A1 1/2021 Verheem  
 2021/0052292 A1 2/2021 Karni  
 2021/0085367 A1 3/2021 Shaddock et al.  
 2021/0128416 A1 5/2021 Danto  
 2021/0145479 A1 5/2021 Ignon et al.  
 2021/0154093 A1 5/2021 Boone, III et al.  
 2021/0154453 A1 5/2021 Ignon et al.  
 2021/0220631 A1 7/2021 Ok et al.  
 2021/0236342 A1 8/2021 Long et al.  
 2021/0236347 A1 8/2021 Carver  
 2021/0236836 A1 8/2021 Schwarz et al.  
 2021/0242657 A1 8/2021 Yi et al.  
 2021/0259914 A1 8/2021 Holbert  
 2021/0267625 A1 9/2021 Carver  
 2021/0268304 A1 9/2021 Lee  
 2021/0275406 A1 9/2021 Danto  
 2021/0282855 A1 9/2021 Boinagrov et al.  
 2021/0283421 A1 9/2021 Kang et al.  
 2021/0290430 A1 9/2021 Kim  
 2021/0330356 A1 10/2021 Del Rosario et al.  
 2021/0353922 A1 11/2021 Ignon et al.  
 2021/0361525 A1 11/2021 Park et al.  
 2021/0370049 A1 12/2021 Moss et al.  
 2021/0370089 A1 12/2021 Anash  
 2021/0393478 A1 12/2021 Bharti  
 2021/0393974 A1 12/2021 Kim et al.  
 2021/0393975 A1 12/2021 Eltorai et al.  
 2021/0395071 A1 12/2021 Zubrum et al.  
 2021/0402208 A1 12/2021 Edgar  
 2022/0001198 A1 1/2022 Lee  
 2022/0001199 A1 1/2022 Beerwerth et al.  
 2022/0008122 A1 1/2022 Johnston et al.  
 2022/0032082 A1 2/2022 Shenfarber et al.  
 2022/0054189 A1 2/2022 Wooten  
 2022/0071491 A1 3/2022 Bae et al.  
 2022/0072332 A1 3/2022 Park et al.  
 2022/0087891 A1 3/2022 Goodman et al.  
 2022/0111198 A1 4/2022 Jung  
 2022/0117632 A1 4/2022 Walker et al.  
 2022/0125706 A1 4/2022 Horinek et al.  
 2022/0126014 A1 4/2022 Cederna et al.  
 2022/0133407 A1 5/2022 Anderson et al.  
 2022/0175443 A1 6/2022 Slatkine et al.  
 2022/0176092 A1 6/2022 Quan et al.  
 2022/0203112 A1 6/2022 Iger et al.  
 2022/0211424 A1 7/2022 Wooten et al.  
 2022/0211988 A1 7/2022 Ignon et al.  
 2022/0218562 A1 7/2022 Capelli et al.  
 2022/0226668 A1 7/2022 Lee et al.  
 2022/0233400 A1 7/2022 Oh et al.  
 2022/0241107 A1 8/2022 Kim et al.  
 2022/0241146 A1 8/2022 Jeong  
 2022/0268536 A1 8/2022 Stephenson et al.  
 2022/0287910 A9 9/2022 Boone, III et al.  
 2022/0312940 A1 10/2022 Hong et al.  
 2022/0362529 A1 11/2022 Castro  
 2022/0401714 A1 12/2022 Quan et al.  
 2022/0409276 A1 12/2022 Choi  
 2023/0012684 A1 1/2023 Ignon et al.  
 2023/0014299 A1 1/2023 Lee, Jr. et al.  
 2023/0018295 A1 1/2023 Ignon et al.  
 2023/0019979 A1 1/2023 Deem et al.  
 2023/0033217 A1 2/2023 Ignon et al.  
 2023/0033761 A1 2/2023 Ignon et al.  
 2023/0042047 A1 2/2023 Kim et al.  
 2023/0062185 A1 3/2023 Nazarian et al.  
 2023/0104221 A1 4/2023 Aharon  
 2023/0123145 A1 4/2023 Ko

## FOREIGN PATENT DOCUMENTS

CA 2340154 9/2002  
 CA 2784209 8/2011  
 CN 1708261 12/2005

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

|    |                   |         |
|----|-------------------|---------|
| CN | 107920948         | 4/2018  |
| CN | 306995346         | 12/2021 |
| DE | 599521            | 7/1934  |
| DE | 2415633           | 10/1975 |
| DE | 3338057           | 8/1984  |
| DE | 3421390           | 12/1985 |
| DE | 234608            | 4/1986  |
| DE | 3503343           | 8/1986  |
| DE | 8330191           | 6/1987  |
| DE | 3740902           | 12/1988 |
| DE | 4237940           | 5/1993  |
| DE | 29808395          | 8/1998  |
| DE | 10-2004-015815    | 11/2005 |
| EP | 0258901           | 9/1987  |
| EP | 0479121           | 4/1992  |
| EP | 0564392           | 3/1993  |
| EP | 0784997           | 7/1997  |
| EP | 1238643           | 4/2000  |
| EP | 1453558           | 9/2004  |
| EP | 2206483           | 7/2010  |
| EP | 2544563           | 9/2015  |
| EP | 2106780           | 3/2016  |
| EP | 2865867           | 5/2016  |
| EP | 3217899           | 5/2016  |
| EP | 2240099           | 2/2018  |
| EP | 2967633           | 4/2018  |
| EP | 3302319           | 4/2018  |
| EP | 3319573           | 5/2018  |
| EP | 3340908           | 7/2018  |
| EP | 2451367           | 1/2020  |
| EP | 3388006           | 3/2020  |
| EP | 2618797           | 4/2020  |
| EP | 3237055           | 8/2020  |
| EP | 3795204           | 3/2021  |
| EP | 3437575           | 4/2021  |
| EP | Des. 8794184-0001 | 12/2021 |
| EP | Des. 8880371-0001 | 5/2022  |
| ES | 1037776           | 4/1998  |
| FR | 2712172           | 5/1995  |
| FR | 2773461           | 7/1999  |
| GB | 1372609           | 10/1974 |
| GB | 2306351           | 5/1997  |
| GB | 2585500           | 1/2021  |
| IT | 553076            | 12/1956 |
| IT | 1184922           | 3/1985  |
| JP | 53-118927         | 8/1963  |
| JP | H05-042060        | 2/1993  |
| JP | 1993-088552       | 12/1993 |
| JP | 1997-294747       | 11/1997 |
| JP | 2003-534881       | 11/2003 |
| JP | 2003-339713       | 12/2003 |
| JP | 2004-275721       | 10/2004 |
| JP | 2006-503627       | 2/2006  |
| JP | 2006-204767       | 10/2006 |
| JP | 2012-527967       | 11/2012 |
| JP | 2013-215621       | 10/2013 |
| JP | D1581877          | 7/2017  |
| JP | D1609357          | 6/2018  |
| JP | 2018-527052       | 9/2018  |
| KR | 20-0280320        | 7/2002  |
| KR | 10-20070070173    | 7/2007  |
| KR | 10-2018-0030607   | 3/2018  |
| KR | 10-1836310        | 3/2018  |
| TW | D214226           | 9/2021  |
| WO | WO 1994/024980    | 11/1994 |
| WO | WO 1997/000707    | 1/1997  |
| WO | WO 1997/011650    | 3/1997  |
| WO | WO 2000/015300    | 3/2000  |
| WO | WO 2000/79540     | 12/2000 |
| WO | WO 2001/93931     | 12/2001 |
| WO | WO 2004/108091    | 12/2001 |
| WO | WO 2003/073917    | 9/2003  |
| WO | WO 2004/037098    | 5/2004  |
| WO | WO 2004/037287    | 5/2004  |
| WO | WO 2005/061042    | 7/2005  |

|    |                |         |
|----|----------------|---------|
| WO | WO 2005/070313 | 8/2005  |
| WO | WO 2006/018731 | 2/2006  |
| WO | WO 2006/031413 | 3/2006  |
| WO | WO 2007/114904 | 10/2007 |
| WO | WO 2008/012324 | 1/2008  |
| WO | WO 2009/086182 | 7/2009  |
| WO | WO 2009/088884 | 7/2009  |
| WO | WO 2009/097451 | 8/2009  |
| WO | WO 2010/022396 | 2/2010  |
| WO | WO 2010/068960 | 6/2010  |
| WO | WO 2010/151704 | 12/2010 |
| WO | WO 2011/006009 | 1/2011  |
| WO | WO 2011/110840 | 9/2011  |
| WO | WO 2012/145667 | 10/2012 |
| WO | WO 2013/030117 | 3/2013  |
| WO | WO 2014/091035 | 6/2014  |
| WO | WO 2014/151104 | 9/2014  |
| WO | WO 2016/052818 | 4/2016  |
| WO | WO 2016/106396 | 6/2016  |
| WO | WO 2017/007939 | 1/2017  |
| WO | WO 2017/111481 | 6/2017  |
| WO | WO 2021/018765 | 2/2021  |
| WO | WO 2021/113343 | 6/2021  |
| WO | WO 2022/099318 | 5/2022  |
| WO | WO 2023/039524 | 3/2023  |
| WO | WO 2023/064718 | 4/2023  |
| WO | WO 2023/164572 | 8/2023  |

## OTHER PUBLICATIONS

File History of Reissue U.S. Appl. No. 11/027,590, filed Dec. 29, 2004 (Reissue of U.S. Pat. No. 6,500, 183, issued Dec. 31, 2002).

File History of Reexamination No. 90/007,683 (Reexamination of U.S. Pat. No. 6,241,739, issued Jun. 5, 2001).

File History of Reexamination No. 90/013,284, filed Jul. 2, 2014 (Reexamination of U.S. Pat. No. 6,241,739, issued Jun. 5, 2001).

Cox III et al., Decreased Splatter in Dermabrasion, Arch Facial Plastic Surgery, Jan.-Mar. 2000, vol. 2, pp. 23-26.

Ditre et al., Effect of  $\alpha$ -hydroxy acids on photoaged skin: A pilot clinical, histologic, and ultrastructural study, Journal of American Academy of Dermatology, Feb. 1996, vol. 34, No. 2, Part 1, pp. 187-195.

Harris et al., Combining Manual Dermabrasion with Low Strength Trichloroacetic Acid to Improve Antinically Injured Skin, The Journal of Dermatologic Surgery and Oncology, Jul. 1994, vol. 20, No. 7, pp. 436-442.

Hydrafacial® Tower—User guide. Edge Systems. Revised Jun. 23, 2016. p. No. 16.

Microdermabrader Pepita Instruction Manual, Mattioli Engineering S.R.L., PEP\_USA2.doc Rev 1.1, Sep. 29, 1997.

Beautimate adjustable Hydra Needle Microneedling Serum Applicator, <https://www.beautimate.com/products/adjustable-hydra-needle>, first accessed Aug. 12, 2023.

Hydrafacial Hydropeel Vortex Fusion Tips, <https://mergesouq.com/products/hydrafacial-hydropeel-vortex-fusion-tips>, first accessed Aug. 12, 2023.

U.S. Appl. No. 09/648,025 (U.S. Pat. No. 6,641,591), filed Aug. 25, 2000, Instruments and Techniques for Controlled Removal of Epidermal Layers.

U.S. Appl. No. 10/699,747 (U.S. Pat. No. 7,789,886), filed Nov. 3, 2003, Instruments and Techniques for Controlled Removal of Epidermal Layers.

U.S. Appl. No. 11/739,615 (U.S. Pat. No. 8,337,513), filed Apr. 24, 2007, Instruments and Techniques for Controlled Removal of Epidermal Layers.

U.S. Appl. No. 11/417,709 (U.S. Pat. No. 8,066,716), filed May 3, 2006, Instruments and Techniques for Controlled Removal of Epidermal Layers.

U.S. Appl. No. 11/417,396 (U.S. Pat. No. 7,678,120), filed May 3, 2006, Instruments and Techniques for Controlled Removal of Epidermal Layers.

U.S. Appl. No. 14/702,509 (U.S. Pat. No. 9,775,646), filed May 1, 2015, Devices and Systems for Treating the Skin Using Vacuum.

(56)

**References Cited****OTHER PUBLICATIONS**

U.S. Appl. No. 14/702,486 (U.S. Pat. No. 9,468,464), filed May 1, 2015, Methods for Treating the Skin Using Vacuum.  
 U.S. Appl. No. 11/392,348 (U.S. Pat. No. 8,048,089), filed Mar. 29, 2006, Apparatus and Methods for Treating the Skin.  
 U.S. Appl. No. 13/267,554 (U.S. Pat. No. 9,474,886), filed Oct. 6, 2011, Removable Tips for Skin Treatment Systems.  
 U.S. Appl. No. 14/698,673 (U.S. Pat. No. 9,550,052), filed Apr. 28, 2015, Console System for the Treatment of Skin.  
 U.S. Appl. No. 14/698,713 (U.S. Pat. No. 9,662,482), filed Apr. 28, 2015, Methods and Systems for Extraction of Materials From Skin.  
 U.S. Appl. No. 14/700,789 (U.S. Pat. No. 9,814,868), filed Apr. 30, 2015, Tip With Embedded Materials for Skin Treatment.  
 U.S. Appl. No. 15/660,750 (U.S. Pat. No. 10/357,641), filed Jul. 26, 2017, Tips for Skin Treatment Device.  
 U.S. Appl. No. 15/660,777 (U.S. Pat. No. 10/357,642), filed Jul. 26, 2017, Removable Tips for Use With Skin Treatment Systems.  
 U.S. Appl. No. 16/517,268 (U.S. Pat. No. 11,446,477), filed Jul. 19, 2019, Devices and Methods for Treating Skin.  
 U.S. Appl. No. 17/165,820 (U.S. Pat. No. 11,547,840), filed Feb. 2, 2021, Devices and Methods for Treating Skin.  
 U.S. Appl. No. 17/165,807 (U.S. Pat. No. 11,612,726), filed Feb. 2, 2021, Devices and Methods for Treating Skin.  
 U.S. Appl. No. 09/294,254 (U.S. Pat. No. 6,162,232), filed Apr. 19, 1999, Instruments and Techniques for High-Velocity Fluid Abrasion of Epidermal Layers With Skin Cooling.  
 U.S. Appl. No. 09/475,480 (U.S. Pat. No. 6,299,620), filed Dec. 30, 1999, Instruments and Techniques for Inducing Neocollagenesis in Skin Treatments.  
 U.S. Appl. No. 09/475,479 (U.S. Pat. No. 6,387,103), filed Dec. 30, 1999, Instruments and Techniques for Inducing Neocollagenesis in Skin Treatments.  
 U.S. Appl. No. 11/370,200, filed Mar. 7, 2006, Microdermabrasion Method And apparatus.  
 U.S. Appl. No. 12/362,353 (U.S. Pat. No. 9,056,193), filed Jan. 29, 2009, Apparatus and Method for Treating the Skin.  
 U.S. Appl. No. 14/734,995 (U.S. Pat. No. 11,020,577), filed Jun. 9, 2015, Devices and Systems for Treating Skin Surfaces.  
 U.S. Appl. No. 17/332,897, filed May 27, 2021, Devices, Systems, and Methods for Treating the Skin.  
 U.S. Appl. No. 17/952,569, filed Sep. 26, 2022, Devices, Systems, and Methods for Treating the Skin.  
 U.S. Appl. No. 17/952,665, filed Sep. 26, 2022, Devices, Systems, and Methods for Treating the Skin.  
 U.S. Appl. No. 12/832,663 (U.S. Pat. No. 8,814,836), filed Jul. 8, 2010, Devices, Systems and Methods for Treating the Skin Using Time-Release Substances.  
 U.S. Appl. No. 14/455,762 (U.S. Pat. No. 9,642,997), filed Aug. 8, 2014, Devices for Treating Skin Using Treatment Materials Located Along a Tip.  
 U.S. Appl. No. 15/588,102 (U.S. Pat. No. 10,556,097), filed May 5, 2017, Devices for Treating Skin Using Treatment Materials Located Along a Tip.  
 U.S. Appl. No. 16/784,850, filed Feb. 7, 2020, Devices and Methods for Treating Skin.  
 U.S. Appl. No. 12/346,582 (U.S. Pat. No. 8,343,116), filed Dec. 30, 2008, Apparatus and Method for Treating the Skin.  
 U.S. Appl. No. 13/620,376 (U.S. Pat. No. 9,486,615), filed Sep. 14, 2012, Microdermabrasion Apparatus and Method.  
 U.S. Appl. No. 15/344,357 (U.S. Pat. No. 10,556,096), filed Nov. 4, 2016, Devices and Methods for Skin Treatment.  
 U.S. Appl. No. 16/784,044, filed Feb. 6, 2020, Devices and Methods for Skin Treatment.  
 U.S. Appl. No. 09/540,945 (U.S. Pat. No. 6,592,595), filed Mar. 31, 2000, Microdermabrasion and Suction Massage Apparatus and Method.  
 U.S. Appl. No. 09/698,409 (U.S. Pat. No. 6,527,783), filed Oct. 27, 2000, Microdermabrasion and Suction Massage Apparatus and Method.

U.S. Appl. No. 10/177,173 (U.S. Pat. No. 6,673,082), filed Jun. 20, 2002, Microdermabrasion Handpiece With Supply and Return Lumens.  
 U.S. Appl. No. 10/315,478 (U.S. Pat. No. 6,942,649), filed Dec. 10, 2002, Microdermabrasion Fluid Application System and Method.  
 U.S. Appl. No. 09/699,220 (U.S. Pat. No. 6,629,983), filed Oct. 27, 2000, Apparatus and Method for Skin/Surface Abrasion.  
 U.S. Appl. No. 14/211,089 (U.S. Pat. No. 10,238,812), filed Mar. 14, 2014, Skin Treatment Systems and Methods Using Needles.  
 U.S. Appl. No. 16/363,310, filed Mar. 25, 2019, Skin Treatment Systems and Methods Using Needles.  
 U.S. Appl. No. 14/211,290 (U.S. Pat. No. 9,566,088), filed Mar. 14, 2014, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 15/430,209 (U.S. Pat. No. 10,251,675), filed Feb. 10, 2017, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 16/376,956 (U.S. Pat. No. 11,717,326), filed Apr. 5, 2019, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 17/952,721, filed Sep. 26, 2022, Devices, Systems, and Methods for Treating the Skin.  
 U.S. Appl. No. 17/952,676, filed Sep. 26, 2022, Devices, Systems, and Methods for Treating the Skin.  
 U.S. Appl. No. 14/774,641 (U.S. Pat. No. 10,172,644), filed Sep. 10, 2015, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 16/241,572 (U.S. Pat. No. 10,993,743), filed Jan. 7, 2019, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 17/163,128, filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 17/163,199 (U.S. Pat. No. 11,517,350), filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 17/163,237 (U.S. Pat. No. 11,202,657), filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 17/163,240 (U.S. Pat. No. 11,213,321), filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 14/998,375 (U.S. Pat. No. 9,498,610), filed Dec. 23, 2015, Devices and Methods for Treating the Skin Using a Rollerball or a Wicking Member.  
 U.S. Appl. No. 15/354,754 (U.S. Pat. No. 10,035,007), filed Nov. 17, 2016, Devices and Methods for Treating the Skin.  
 U.S. Appl. No. 16/040,397, filed Jul. 19, 2018, Devices and Methods for Treating the Skin.  
 U.S. Appl. No. 17/164,580, filed Feb. 1, 2021, Devices and Methods for Treating the Skin.  
 U.S. Appl. No. 15/498,416 (U.S. Pat. No. 10,179,229), filed Apr. 26, 2017, Devices and Methods for Treating the Skin Using a Porous Member.  
 U.S. Appl. No. 16/246,306 (U.S. Pat. No. 11,224,728), filed Jan. 11, 2019, Devices and Methods for Treating the Skin Using a Porous Member.  
 U.S. Appl. No. 17/576,888, filed Jan. 14, 2022, Devices and Methods for Treating the Skin.  
 U.S. Appl. No. 15/204,939 (U.S. Pat. No. 11,241,357), filed Jul. 7, 2016, Devices, Systems and Methods for Promoting Hair Growth.  
 U.S. Appl. No. 17/592,432, filed Feb. 3, 2022, Devices, Systems and Methods for Improving Scalp Health.  
 U.S. Appl. No. 18/035,723, filed May 5, 2023, Devices, Systems and Methods for Treating the Skin.  
 U.S. Appl. No. 29/811,066, filed Oct. 11, 2021, Skin Treatment System.  
 U.S. Appl. No. 29/807,430, filed Sep. 10, 2021, Skin Treatment Device.  
 U.S. Appl. No. 29/807,428, filed Sep. 10, 2021, Container for a Skin Treatment Device.  
 U.S. Appl. No. 29/829,476, filed Mar. 4, 2022, Light Therapy Device for Skin Care.  
 U.S. Appl. No. 29/811,070, filed Oct. 11, 2021, Skin Treatment Tip.  
 U.S. Appl. No. 29/826,153, filed Feb. 9, 2022, Dual Treating Device for Treating Acne or Wrinkles.  
 U.S. Appl. No. 29/854,067, filed Sep. 21, 2022, Treatment Device for Skin.  
 U.S. Appl. No. 29/884,441, filed Feb. 10, 2023, Skin Treatment Tip.  
 U.S. Appl. No. 15,1344,357 (U.S. Pat. No. 10,556,096), filed Nov. 4, 2016, Devices and Methods for Skin Treatment.  
 U.S. Appl. No. 14/211,089 (U.S. Pat. No. 10,238,812), filed Mar. 4, 2014, Skin Treatment Systems and Methods Using Needles.

(56)

**References Cited**

OTHER PUBLICATIONS

U.S. Appl. No. 14/774,641 (U.S. Pat. No. 10,177,644), filed Sep. 10, 2015, Devices, Systems and Methods for Treating the Skin.

U.S. Appl. No. 15/204,939 (U.S. Pat. No. 11,241,357), filed Jul. 7, 2016, Devices and Methods for Systems Promoting Hair Growth.

U.S. Appl. No. 29/807,428, Sep. 10, 2021, Container for a Skin Treatment Device.

\* cited by examiner






FIG. 1

FIG. 2A









FIG. 3






FIG. 5B




FIG. 5D




FIG. 5A








FIG. 5C






FIG. 7B




FIG. 7D




FIG. 7A
















FIG. 7C












FIG. 12




FIG. 13A




FIG. 13B




*FIG. 14A*




*FIG. 14B*




FIG. 15A




FIG. 15B




FIG. 15C




*FIG. 15D*




*FIG. 15E*




FIG. 16





FIG. 17






FIG. 19

1

**DEVICES AND METHODS FOR TREATING SKIN**

## REFERENCE TO RELATED APPLICATIONS

This is a continuation of U.S. patent application Ser. No. 17/165,820 filed Feb. 2, 2021, which is a continuation of U.S. patent application Ser. No. 16/517,268 filed Jul. 19, 2019 and issued as U.S. Pat. No. 11,446,477 on Sep. 20, 2022, which is a continuation of U.S. patent application Ser. No. 15/660,750 filed Jul. 26, 2017 and issued as U.S. Pat. No. 10,357,641 on Jul. 23, 2019, which is a continuation of U.S. patent application Ser. No. 14/700,789 filed Apr. 30, 2015 and issued as U.S. Pat. No. 9,814,868 on Nov. 14, 2017, which is a continuation of U.S. patent application Ser. No. 13/267,554 filed Oct. 6, 2011 and issued as U.S. Pat. No. 9,474,886 on Oct. 25, 2016, which is a continuation of U.S. patent application Ser. No. 11/392,348 filed Mar. 29, 2006 and issued as U.S. Pat. No. 8,048,089 on Nov. 1, 2011, which claims the benefit of U.S. Provisional Application No. 60/755,310 filed Dec. 30, 2005 and U.S. Provisional Application No. 60/764,668 filed Feb. 2, 2006. The entireties of all of the aforementioned applications are hereby incorporated by reference herein.

## BACKGROUND

## Field

The invention relates in general to the field of skin treatment, and more specifically to apparatuses and methods for treating a person's skin.

## Description of the Related Art

Abrasion of the outer layer or epidermis of the skin is desirable to smooth or blend scars, blemishes, or other skin conditions that may be caused by, for example, acne, sun exposure, and aging. Standard techniques used to abrade the skin have generally been separated into two fields referred to as dermabrasion and microdermabrasion. Both techniques remove portions of the epidermis called the stratum corneum, which the body interprets as a mild injury. The body then replaces the lost skin cells, resulting in a new outer layer of skin. Additionally, despite the mild edema and erythema associated with the procedures, the skin looks and feels smoother because of the new outer layer of skin.

Dermabrasion refers to a procedure in which the surface of the skin is removed due to mechanical rubbing by a handpiece with an abrasive element that is often in the form of a burr, wheel, or disc. This process tends to be painful and messy. In fact, the procedure is sometimes painful enough to require a local anesthetic. Dermabrasion leaves the skin red and raw-looking. The removed skin can take several months to regrow and heal. Recent efforts have led to the use of lasers instead of abrasive elements, which have resulted in less bleeding, but the pain and mess remains.

Efforts have been made to decrease the mess caused by the process waste, such as removed skin and blood, by adding a suction element. As the process waste is drawn into the suction opening, skin that has not been removed is also pulled against the grit surrounding the suction opening, so the procedure remains fairly messy due to the abrasion that takes place outside of the handpiece by the grit.

Microdermabrasion refers generally to a procedure in which the surface of the skin is removed due to mechanical rubbing by a handpiece emitting a stream of sand or grit. For

2

example, a handpiece can be used to direct an air flow containing tiny crystals of aluminum oxide, sodium chloride, or sodium bicarbonate. The momentum of the grit tends to wear away two to three cell layers of the skin with each pass of the handpiece. Alternatively, new "crystal-free" microdermabrasion techniques utilize a diamond-tipped handpiece without a stream of grit.

Efforts to add a suction element have been more successful in microdermabrasion than in dermabrasion because the handpiece applying the stream of grit is more controllable to a localized area. That is, as the removed skin is drawn into the suction opening, skin that has not been removed is also pulled towards the handpiece where it is treated with the grit stream, allowing for simultaneous local treatment and suction.

Microdermabrasion removes moisture from the skin, so the procedure is always followed by the application of moisturizing creams. However, similar to topical application of moisturizing creams prior to microdermabrasion, the moisturizing elements only work as deep as the active ingredients can passively migrate through the remaining epidermis.

## SUMMARY

In some embodiments, an apparatus for treating skin has a console with a user input device and a handpiece assembly. The handpiece assembly is configured to treat skin. A fluid line provides fluid communication between the console and the handpiece assembly. A manifold system is coupled to the console and controlled by the user input device, such as a computer, touchscreen, keyboard, and the like. The manifold system is configured to hold releasably a plurality of fluid sources and deliver fluid from at least one of the plurality of fluid sources to the handpiece assembly.

In some embodiments, a tip comprising a skirt portion is configured to couple to a handpiece for treating a target area on a patient's skin. A central body portion is coupled to the skirt portion. A first passage extends through the central body portion and is configured to receive a fluid from the handpiece. At least one second passageway extending through the central body portion and is configured to convey the fluid back into the handpiece. An inner member extends in a generally spiral fashion across at least a portion of a distal face of the central body portion. The inner member defines a channel between the first passage and the at least one second passage. When the tip is placed against the skin, a chamber can be formed by the channel and the person's skin.

In some embodiments, a method of treating a target region on a patient's skin comprises providing a tip including a first aperture and at least one second aperture. At least one inner member on the surface of the tip defines at least one channel between the first aperture and the at least one second aperture. An outer member is disposed on the surface of the tip. The outer member engages the target with the tip. A treatment fluid flows distally through the first aperture region and through the at least one channel. The treatment fluid flows proximally through the at least one second aperture.

In some embodiments, a tip comprises a skirt portion configured to couple to a handpiece for treating a target on a patient's skin. A central body portion is coupled to the skirt portion and includes a mounting region substantially opposite the skirt portion. The mounting region configured to receive a pad for treating the skin. A first aperture extends through the skirt portion and the central body portion and

3

configured to receive a fluid from the handpiece. At least one second aperture extending through the skirt portion and the central body portion and configured to convey the fluid back into the handpiece.

In some embodiments, a method of treating a target region of a patient comprises providing a tip including a first aperture, at least one second aperture, and a distal end configured to receive a pad. In some variations, the first pad is attached to the distal end. The tip is engaged with the target region.

In some embodiments, a manifold system comprises a body portion configured to receive releasably at least two bottles. The manifold is configured so that it can be coupled to a console. The console includes a handpiece for treating skin. At least one elongate member is in communication with a pump and configured to extract a fluid from one of the at least two bottles. At least one switch is configured to permit or inhibit a flow of the fluid from one of the at least two bottles through the pump. In some variations, the elongate member is dimensioned to fit within one of at least two bottles to draw fluid out of the bottle.

In some embodiments, a method of treating a target region on a patient's skin comprises engaging a tip with the patient's skin such that an effective amount of skin is removed by the tip. In some variations, the tip is a dry tip. After removing an effective amount of skin, another tip (e.g., a wet tip) engages the patient's skin such that an effective amount of skin is removed by the tip. In some variations, acid is delivered out of the wet tip to facilitate skin removal. In some variations, the wet tip includes a first aperture, at least one second aperture, at least one inner member on the surface of the tip defining at least one channel between the first aperture and the at least one second aperture, and an outer member on the surface of the tip. In some variations, treatment fluid flows outwardly along the channel. In some variations, treatment fluid flows inwardly along the channel. In some variations, the wet tip comprises an abrasive pad.

In some embodiments, a method of treating a target region on a patient's skin comprises engaging a first skin treatment tip with the patient's skin. A first material is delivered out of the first skin treatment tip to a target region. A second skin treatment tip engages the target region while the first material effectively facilitates exfoliation with the second skin treatment tip. In some variations, the first material comprises an acid, hydrator, and combination thereof. In some variations, the first skin treatment tip is configured to remove skin at a different rate than the second skin treatment tip. In some variations, the first skin treatment tip is configured to exfoliate at a higher rate than the second skin treatment tip. In some variations, material is delivered out of the second treatment tip to the target region of the patient's skin.

The apparatus for treating skin can dispense treatment material that is held in containers, such as bottles, bags, pouches, or other suitable structures for holding and storing material. These containers can be non-refillable or refillable. The treatment material can be delivered by gravity feed, pumps, or suction devices. The manifold system can be used to control fluid flow from a plurality of containers to one or more handpieces.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Having thus summarized the general nature of the invention, certain preferred embodiments and modifications thereof will become apparent to those skilled in the art from the detailed description herein having reference to the figures that follow.

4

FIG. 1 is a perspective view of one embodiment of a skin treatment system.

FIG. 2A is a perspective view of one embodiment of a handpiece assembly for use with the skin treatment system of FIG. 1.

FIG. 2B is a side elevational view of the handpiece assembly of FIG. 2A.

FIG. 3 is a longitudinal cross-sectional view of the handpiece assembly of FIG. 2B. The handpiece assembly is engaging a person's skin.

FIG. 4 is a perspective view of another embodiment of a handpiece assembly.

FIG. 5A is a perspective view of one embodiment of a tip that can be coupled to a main body of a handpiece assembly to treat a person's skin.

FIG. 5B is a top elevational view of the tip of FIG. 5A.

FIG. 5C illustrates a bottom elevational view of the tip of FIG. 5A.

FIG. 5D is a cross-sectional view of the tip of FIG. 5B taken along the line 5D-5D.

FIG. 6A is a perspective view of a tip in accordance with another embodiment.

FIG. 6B is a top elevational view of the tip of FIG. 6A.

FIG. 6C is a bottom elevational view of the tip of FIG. 6A.

FIG. 6D is a cross-sectional view of the tip of FIG. 6B taken along the line 6D-6D.

FIG. 7A is a perspective view of a tip in accordance with another embodiment.

FIG. 7B is a top elevational view of the tip of FIG. 7A.

FIG. 7C is a bottom elevational view of the tip of FIG. 7A.

FIG. 7D is a cross-sectional view of the tip of FIG. 7B taken along the line 7D-7D.

FIG. 8A is a perspective view of yet another embodiment of a tip for treating a person's skin.

FIG. 8B is a top elevational view of the tip of FIG. 8A.

FIG. 8C is a bottom elevational view of the tip of FIG. 8A.

FIG. 8D is a cross-sectional view of the tip of FIG. 8B taken along the line 8D-8D.

FIG. 9A is a perspective view of still another embodiment of a tip that can be coupled to a main body of a handpiece assembly.

FIG. 9B is a top elevational view of the tip of FIG. 9A.

FIG. 9C is a bottom elevational view of the tip of FIG. 9A.

FIG. 9D is a cross-sectional view of the tip of FIG. 9B taken along the line 9D-9D.

FIG. 10A is a perspective view of another embodiment of a tip for treating a person's skin.

FIG. 10B is top elevational view of the tip of FIG. 10A.

FIG. 10C is bottom elevational view of the tip of FIG. 10A.

FIG. 10D is a cross-sectional view of the tip of FIG. 10B taken along the line 10D-10D.

FIG. 10E is a perspective exploded view of the tip of FIG. 10A, wherein a pad is spaced from a tip main body.

FIGS. 11A-11E are cross-sectional views of inner members that can be used to exfoliate skin.

FIG. 12 is a perspective view of a bottle for use with the skin treatment system of FIG. 1.

FIG. 13A is a cross-sectional view of one embodiment of a bottle spaced from an insertion tip assembly.

FIG. 13B is a cross-sectional view of the bottle of FIG. 13A coupled with the insertion tip assembly.

FIG. 14A is a cross-sectional view of a closure and a bottle.

FIG. 14B is a cross-sectional view of the closure and bottle of FIG. 14A when assembled.

5

FIG. 15A is a perspective view of one embodiment of a manifold system holding a plurality of bottles.

FIG. 15B is a cross-sectional view of the manifold system of FIG. 15A taken along the line 15B-15B of FIG. 15A.

FIG. 15C is a cross-sectional view of the manifold system of FIG. 15A taken along the line 15C-15C of FIG. 15A.

FIG. 15D is a cross-sectional view of the manifold system of FIG. 15C wherein the bottle has been removed.

FIG. 15E is a cross-sectional elevational view of the manifold system.

FIG. 16 is a perspective view of another embodiment of a skin treatment system.

FIG. 17 is a cross-sectional view of a fluid line of the skin treatment system of FIG. 16 taken along the line 17-17.

FIG. 18 is a side elevational view of a handpiece assembly with a removable cartridge.

FIG. 19 is a side elevational view of the handpiece assembly and removable cartridge of FIG. 18, the cartridge is shown removed from the handpiece assembly.

#### DETAILED DESCRIPTION

FIG. 1 illustrates a skin treatment system 10 that can be used to perform one or more treatments on a person's skin. The illustrated skin treatment system 10 includes a console 12 and a handpiece assembly 18 connected to the console 12 via a line 20. A manifold system 24 can control the flow of treatment material from containers 26 into and through the line 20. The treatment material can be discharged out of the handpiece assembly 18 to treat a person's skin. The skin treatment system 10 can be used at a hospital, health care physicality, residences, or any other suitable location.

As explained in more detail below, the handpiece assembly 18 is applied to the target area of the patient to perform skin treatment(s). As used herein, the term "skin treatment" is a broad term and includes, but is not limited to, skin removal, skin abrasion (e.g., dermabrasion, microdermabrasion, etc.), ablating or slicing skin (preferably a thin layer of skin), stimulation (including thermal, mechanical, electrical, and/or chemical stimulation), mesotherapy, isophoresis, light therapy, vacuum therapy, and the like. Preferably, the handpiece assembly 18 administers a treatment material from at least one of the containers 26 through the line 20 to the target area of the skin while the handpiece assembly 18 engages the skin.

As used herein, the term "treatment material" is a broad term and includes, but is not limited to, medicament, a substance tending to flow or conform to the outline of its container such as fluid, gas, liquid (e.g., serums, water, saline, etc.), gel, fluidized material, additives, and/or a plurality of fine solids. The general term "fluid" is used throughout synonymously with the term "treatment material" and is to be given the same broad definition. The handpiece assembly 18 can preferably massage, abrade, ablate, or otherwise treat the target skin area while also applying a treatment material to the patient. In certain embodiments, the treatment material and tip of the handpiece 18 can work in combination for an effective and rapid skin treatment. Additionally, any number of "dry" and "wet" tips can be used alone or in combination for treatment flexibility.

With continued reference to FIG. 1 the line 20 is configured to provide fluid communication between the containers 26 and the handpiece assembly 18. The line 20 can comprise one or more conduits extending between the console 12 and the handpiece assembly 18. In certain embodiments, the line

6

20 includes a supply line and a waste line for delivering and returning material, respectively, as detailed below.

The distal end 22 of the line 20 is connected to the handpiece assembly 18. Preferably, the line 20 includes a filter 28 that removes contaminants or impurities from the treatment material passing through the line 20. In other embodiments, the filter 28 is located in the console 12 or the manifold system 24. The console 12 can be connected to a power source such as an AC outlet. The power source can power the handpiece assembly 18 and/or other components of the skin treatment system 10, such as, for example, pumps, valves, and the like.

In the illustrated embodiment, the console 12 comprises four casters 33 to allow for easy movement, for example, from one treatment room to another treatment room. In such an embodiment, the console 12 can be conveniently rolled on a support surface. Other means of transportation can also be employed or the console 12 can be stationary. In some embodiments, the console 12 is portable for convenient transport.

The illustrated containers 26 of FIG. 1 are preferably releasably coupled to the manifold system 24. The manifold system 24 can deliver treatment material from the containers 26 to the line 20 as mentioned above. In certain embodiments, the console 12 has a user input device 32 for selecting a treatment material to be passed through the line 20 to the handpiece assembly 18. During some skin treatment procedures, treatment materials from multiple containers 26 are sequentially or simultaneously applied to the patient's skin during a "wet" mode of operation. Alternatively, the skin treatment system 10 can be used to deliver a single treatment material to the patient's skin. In some embodiments, the console 12 can be used for a "dry" mode of operation. That is, the console 12 can be used to exfoliate skin, for example, without delivering little or substantially no treatment fluid. The skin treatment system 10 can thus provide flexibility in selecting a treatment plan.

Multiple handpieces assemblies 18 and/or tips 34 can be used during a single skin treatment procedure in a wet and/or dry mode of operation. For example, a first handpiece assembly 18 may be employed to treat a patient's face and neck while a second handpiece assembly 18 may be employed to treat other larger areas of the patient's body. Thus, different handpieces 18 can be used to treat different regions of a person's body. The configurations of the handpieces 18 and tips can be selected based on the treatment material to be applied, desired interaction with the patient's skin, size of treatment area, skin condition, and the like.

With reference to FIGS. 2A and 2B, the handpiece assembly 18 includes a main body 30 and a tip 34. The handpiece assembly 18 can be conveniently held within the hand of a user so that the user can place the tip 34 in operative engagement with a person's skin. The user is typically an aesthetician (e.g., an aesthetician allowed to perform microdermabrasion), doctor, and other medical personnel, such as a physician assistant and nurse practitioner. In some cases, the user is the person whose skin is being treated.

The main body 30 has contoured portions 70 at its distal end 36 so that the user can comfortably grip the handpiece assembly 18 during use. The main body 30 can have other designs to provide a comfortable grip. FIG. 2A illustrates an embodiment in which the main body 30 is substantially flat on two opposing sides. FIG. 4 illustrates an embodiment in which the main body 30 is generally cylindrical.

As noted above, the tip 34 can be pressed against a patient's skin to perform a skin treatment. The distal end 102 of the tip 34 may be angled with respect to the handpiece

7

assembly 18 to increase the contact area with the patient's skin without enlarging the handpiece assembly 18 for an ergonomic and comfortable design. The angled tip 34 can lay flat on the skin while the main body 30 is angled to the skin. The angle between the face of the distal end 102 and the longitudinal axis of the handpiece assembly 18 can be selected based on the desired size of the face of the distal end 102. In alternative embodiments, the face of the distal end 102 is generally perpendicular to the longitudinal axis of the main body 30.

The tip 34 can be permanently or temporarily coupled to the distal end 36 of the main body 30. In some embodiments, the tip 34 is disposable. As used herein, the term "disposable," when applied to a system or component (or combination of components), such as a tip, container, or pad, is a broad term and means, without limitation, that the component in question is used a finite number of times and then discarded. Some disposable components are used only once and then discarded. Other disposable components are used more than once and then discarded. In some embodiments, the tip 34 is removably coupled to the main body 30 such that the tip may be removed from the main body 30 and thrown away to avoid cross-contamination. In other embodiments, the tip 34 is a reusable tip that can be cleaned, for example by autoclaving, after each use. The tip 34 can thus be used for any number of procedures as desired.

With reference to FIGS. 2A and 2B, the proximal end 40 of the main body 30 is operatively connected to the line 20. In the embodiment illustrated, the line 20 includes an output line 50 for removing waste from the handpiece assembly 18 and an input line 52 for delivering treatment material to the handpiece assembly 18. The proximal end 40 of the main body 30 includes a plurality of connectors 44, 46, each connected to one of the conduits 50, 52. The illustrated input line 52 is connected to the connector 46, and the output line 50 is connected to the connector 44.

The input line 52 delivers treatment material from at least one of the containers 26 to the connector 46. The fluid then flows through the main body 30 and ultimately to the tip 34. As shown in FIG. 3, the main body 30 comprises a plurality of lumens 90, 92 in a fluid communication with the tip 34. Fluid from the input line 52 can flow through the input lumen 92 to the tip 34. The fluid then flows out of the tip 34 to a target skin area. The fluid is then trapped in the space 100 between the skin 80 and the tip 34. To remove the fluid, the fluid flows proximally through the lumen 90 to the output line 50. The fluid passes through the output line 50 and into the console 12. As such, fluid can continuously or intermittently flow through the handpiece assembly 18.

To treat the person's skin 80, the handpiece assembly 18 can also be moved relative to the skin 80 such that the tip 34 maintains engagement with the skin 80. The illustrated tip 34 is configured to massage the skin 80 while also providing fluid communication with the skin 80. As detailed below in connection with FIGS. 5A through 10, the tip can include sharp planing blades, blades (e.g., razor blades), raised sharp areas, molded posts, grits, or other structures for treating skin, as detailed below.

When the tip 34 and treatment material are used in combination, the handpiece assembly 18 preferably exfoliates dead skin cells and extracts impurities by applying a vacuum while simultaneously bathing the healthy underlying skin with active treatment material. The active treatment material can facilitate cleansing, exfoliating, hydrating, and/or provide residual antioxidant protection. The treatment material and tip 34, alone or in combination, can effectively and rapidly treat the target skin area. The waste material,

8

including the used treatment material, removed skin, and/or grit, can then be drawn back through the tip 34, the main body 30 via lumen 90, and into the connector 44. The waste then flows into the output line 50 for subsequent disposal, as detailed below in connection with FIG. 4.

In some embodiments, including the illustrated embodiment of FIG. 3, the tip 34 has a tip connector 98 (see FIGS. 5C and 5D) that mates with the lumen 92. The tip 34 can provide fluid communication from the tip connector 98 to the space 100 via a through-hole 122. One or more through-holes 114 define fluid passageways through the tip 34 between the space 100 and the intermediate chamber 116.

The intermediate chamber 116 can be interposed between the through-holes 114 and the lumen 90. The intermediate chamber 116 is preferably defined by the distal face 43 of the main body 30 and the proximal face 41 of the tip 34. The intermediate chamber 116 can provide equalization of fluid between the tip 34 and the body 30. As such, a generally equal vacuum is applied to both through-holes 114. The fluid can flow through the through-holes 114, into the intermediate chamber 116, and then into the lumen 90. In some embodiments, however, the fluid flows directly from the through-holes 114 to the lumen 90 without passing through an intermediate chamber 116.

The tip 34 can have one or more sealing members to form a fluidic seal between the tip 34 and the main body 30. The illustrated main body 30 includes a sealing member 47 that engages the inner surface of the skirt 64 of the tip 34. The sealing member 47 can be a compliant member comprising rubber, polymer, plastic, or other suitable material for forming seals. In some embodiments, the sealing member 47 is an O-ring made of rubber.

With continued reference to FIG. 3, during use, treatment material can flow distally through the lumen 92 into the through-hole 122. The treatment material then proceeds through and out of the through-hole 122 into the space 180. Preferably, the treatment material spreads radially outward to the peripheral through-holes 114. The material can then flow through the through-holes 114 into the lumen 90 for subsequent removal.

In alternative embodiments, the fluid flows in the opposite direction. That is, the line 50 delivers fluid through the lumen 90 into the tip 34. The fluid flows through the intermediate chamber 116 and the through-holes 114. The fluid then flows to the chamber 100 and inwardly through the tip connector 98 to the lumen 92. The fluid proceeds proximally along the lumen 92 and ultimately into the line 52.

In yet another embodiment, the handpiece assembly 18 comprises two or more input lumens 90. Such a design allows mixing of two or more treatment materials within the handpiece assembly 18 or space 100, which would be useful for treatments with fluids that react or are unstable or degrade when stored or mixed.

As depicted in FIG. 4, the handpiece assembly 18 can optionally include a controller 60 that is configured to control the fluid flow out of the tip 34. The illustrated controller 60 can be operated to increase or decrease the flow rate of treatment fluid out of the tip 34. Alternatively or additionally, the controller 60 may control the flow rate of waste fluid flowing through the handpiece assembly 18 to the output line 50. When control of the waste treatment fluid and waste fluid is independent, the detention time of the fluid in the tip 34 may be adjusted as desired.

The illustrated controller 60 is a generally cylindrical body that is pivotally connected to the main body 30. FIG. 4 illustrates an embodiment in which the controller 60 is

recessed into and partially hidden by the main body 30, although in other embodiments the controller 60 may encircle the main body 30. The controller 60 may include textured grooves to provide for easier manipulation. In some embodiments, the controller 60 is located near the distal end 36 of the handpiece assembly 18 proximal or distal of the contoured portion 70. The type and configuration of the controller 60 can be selected based on the design of the handpiece assembly 18. The controller 60 can also be a rotatable knob or handle, digital controller, and the like.

The handpiece assembly 18 can also include one or more flow rate controllers within the main body 30 that cooperate with the controller 60 to adjust the fluid flow out of the tip 34. For example, the controller 60 may comprise a flow control valve such as a globe valve, butterfly valve, needle valve, or variable orifice. Other types of flow rate controllers can also be used, such as an electrically controlled solenoid valve. In embodiments where the fluid flow is electronically controlled, the valve system may alternatively be located in the console 12 or manifold system 24. Separate devices can also be used to control the flow of treatment material. For example, clamps, pinch valves, or other suitable devices can be used to control fluid flow through the lines 50, 52.

Various types of tips 34 can be used with the handpiece assemblies 18 illustrated in FIGS. 1 to 4. FIGS. 5A through 10E illustrate embodiments, for example, of tips 34 that can be used with these handpiece assemblies 18. These tips 34 can be interchangeable to provide maximum treatment flexibility.

As shown in FIGS. 5A through 10E, the tip 34 comprises the skirt 64 and a tip main body 66 extending outwardly therefrom. The skirt 64 is preferably configured to provide a gripping surface suitable for applying leverage or force sufficient to remove the tip 34 from the main body 30. In some embodiments, the skirt 64 includes internal threads such that it can be mechanically coupled to external threads on the distal end 36 of the main body 30. In some embodiments, the tip 34 can be press fit onto the main body 30. Frictional forces can retain the tip 34 to the main body 30.

With respect to FIGS. 5A through 7, the tip 34 comprises an outer member 120 and an inner member 124. The outer member 120 preferably defines the periphery of the distal end 102 of the tip 34. When the tip 34 is placed against skin, the outer member 120 can inhibit fluid flow between the tip 34 and the skin and define the outer portion of the space 100.

The inner member 124 is preferably spaced from the outer member 120 to define one or more channels. The illustrated outer member 120 defines a continuous channel 140 that extends outwardly from the central through-hole 122 towards at least one of the outer through-holes 114. The inner member 120 can form the sidewalls of the channel 140. Any suitable configuration of channels 140 can be used to provide fluid flow along a flow path. The illustrated channels 140 have a somewhat U-shaped axial cross-sectional profile, as depicted in FIG. 8A. The channel 140 can have a V-shaped, curved, or any other suitable cross sectional profile. A flow path between the through-holes in the tip 34 can be defined at least in part by the channels.

The spiral-like pattern of the inner members 124 in FIGS. 5 through 7 varies. For example, the inner member 124 in FIG. 5 extends about a longitudinal axis 143 of the tip 34 approximately one and a half times, the inner member 124 in FIG. 6 extends about the tip 34 approximately two and a half times, and the inner member 124 in FIG. 7 rotates about the tip 34 approximately one and three quarters times. In some embodiments, the inner member 124 subtends an angle of about 70°, 135°, 180°, 210°, 225°, 270°, 315°, 360°,

and angles encompassing such ranges. In yet other embodiments, the inner member 124 subtends an angle of about 405°, 450°, or 495°. The tightness of the spiral in combination with the location and number of through-holes 114 affects the detention time of the fluid in the channel 140. Generally, a tighter spiral results in a longer the pathway (i.e., the length of the channel 140) from delivery through-hole 122 to the return through-holes 114. Fluid traveling down the longer pathway is in contact with the person's skin 80 for a longer period of time. Thus, tighter spirals lead to increased contact time between the fluid and the skin 80. These longer contact times can increase the effectiveness of the fluid because the skin can absorb an adequate amount of active ingredients of the treatment material. Fluid retention time on the patient's skin can be increased to increase hydration, serum retention, and the like. Shorter pathways can be used to reduce contact time between the fluid and the patient's skin. In some embodiments, for example, the tip 34 of FIGS. 5A to 5D has a relatively short pathway to limit absorption of fluids, achieve relatively high flow rates, and the like.

Additionally, the inner members 124 can be configured to remove tissue. The inner member 124 can be an abrasive member designed to remove tissue when the inner member 124 slides along a person's skin. The user may select a tip 34 based on the appropriate detention time and abrasiveness for the treatment being applied. For example, the tip 34 illustrated in FIG. 7 will provide less abrasion than the tip 34 illustrated in FIG. 6, but the tip 34 illustrated in FIG. 7 will provide a longer detention time than the tip 34 illustrated in FIG. 5.

The illustrated tip 34 includes a generally continuous inner member 124 that extends from near the through-hole 122 towards at least one of the through-holes 114. In other embodiments, the tip 34 can have a plurality of inner members 124. For example, the inner members 124 can be linear, curved, and may be continuous or discontinuous.

The handpiece assembly 18 can be moved while the spiral-like inner member 124 engages the patient's skin. The movement of the handpiece assembly 18 can increase the effectiveness of the treatment material expelled out of the tip 34. In some embodiments, for example, the tip 34 can be used with a lifting treatment material that facilitates extractions of, for example, sebum, blackheads, skin, or other substances (e.g., oils, dead skin, etc.). The lifting treatment extraction producer can unclog pores to improve the treated skin's overall appearance. To facilitate extractions, the handpiece assembly 18 can be twisted or rotated while the tip 34 is pressed against the patient's skin. The twisting action and the lifting treatment material can work in combination for effective extractions. In alternative embodiments, a handpiece assembly 18 can also be used without a lifting treatment material for extractions by employing the twisting motion.

In certain embodiments, the spiral-like tip 34 massages the skin 80. In other embodiments, the spiral-like tip 34 ablates the skin 80. For example, the inner members 124 may act as blades to cut thin layers from the skin 80 when the user twists the handpiece assembly 18. Twisting the handpiece assembly 18 causes the tip 34 to rotate about the twisting axis, rotating the sharp inner members 124 against the skin 80, which causes ablation. Thin layers of skin can thus be removed by the handpiece assembly 18. Additionally or alternatively, the spiral-like tip 34 may plane along skin when a fluid is applied to the skin. The planing tip 34 can remove a thin layer of the skin (e.g., the stratum corneum,

## 11

preferably hydrated stratum corneum). Accordingly, the user can use the handpiece assembly 18 to remove a particular amount of skin.

A vacuum can be applied by the handpiece assembly 18. For example, the console 12 can have a pump that applies a vacuum via the output line 52. The negative pressure draws waste material into the through-holes 114 and out of the handpiece assembly 18. When the tip 34 engages the patient's skin, the vacuum can draw the skin against the tip 34 to enhance the effectiveness of the inner members 124. The vacuum can be increased or decreased to increase or decrease, respectively, for example, frictional forces, depth of cutting, amount of abrasion, and the like. To rapidly remove skin, a strong vacuum can be applied to the person's skin so that the skin is pulled against the inner member 124. The vacuum can also facilitate removal of the waste fluid captured between the tip 34 and the patient's skin. A vacuum can also be used in combination with the tips illustrated in FIGS. 1-10E. The vacuum can also be varied based on the thickness, compliance, and other properties of the skin surface

The tip 34 can have any suitable number of through-holes 114, 122 to achieve the desired fluid flow between the skin 80 and the tip 34. For example, FIG. 5A to 5D illustrate an embodiment with two through-holes 114. The number of through-holes 114, 122 can be chosen based on the cross-sectional areas of the through-holes 114, 122 and the expected flow rate of the fluid through the channel 100. Preferably, one end of through-holes 114 is positioned between the inner member 124 and the outer member 120. In some embodiments, including the embodiments illustrated in FIGS. 5A through 7, the through-holes 114 are positioned generally midway between the outer member 120 and inner member 124.

The tips can also have one or more energy sources for delivering energy to the skin. Radiant energy, heat, and the like can be delivered to the skin by the tips. The tip 34 illustrated in FIGS. 6A to 6D has a pair of energy sources 151 in the form of LEDs. When the tip 34 is proximate the patient's skin, the LEDs 151 can deliver a desired amount of energy to the skin. The illustrated tip 34 has four LEDs; however, any number of LEDs can be employed.

In alternative embodiments, the tips can carry deployable material. The structure 151 can be in the form of a cavity or pocket that contain and carry material that is released when it engages the treatment fluid. The material in the cavities 151 can be made of any of the treatment materials disclosed herein, and can be in a solid form. For example, the cavities can hold lubricant or soap that is released when the tip is applied to skin.

FIGS. 8A through 8D illustrate another embodiment of a tip 34 when the inner member 124 includes a ring with perforations 140 that provide fluid communication between the through-hole 122 and through-holes 114. A space 100 can be defined between the inner member 124, perforations 140, and outer member 120 when the tip 34 is in operative engagement with the skin 80. FIG. 8C illustrates an embodiment with eight through-holes 114. In the embodiment illustrated in FIGS. 8A through 8D, the inner member 124 forms recessed regions 171, allowing for a larger area of fluid contact with the skin 80 than the tips 34 illustrated in FIGS. 5 through 7.

FIGS. 9A through 9D illustrate another embodiment of a tip 34 comprising an outer member 120 and an array of protruding inner members 124. A recessed region 191 is defined between the inner members 124 and the outer member 120. The inner members 124 of FIGS. 9A to 9D can

## 12

be posts that are similar to the inner members described above. The post 124, for example, can have relatively sharp edges. These edges can be used to remove skin. In some embodiments, the inner members 124 can have relatively sharp planing blades. The tip 34 illustrated in FIGS. 9A through 9D allows for more freedom of movement of the treatment fluid. The protruding inner members 124 preferably abrade the skin differently than the tips 34 illustrated in FIGS. 5A through 8. Rather than being able to ablate large sections of the skin 80 like a blade, as the tips 34 in FIGS. 5A-8 can do in certain embodiments, the plurality of protruding inner members 124 can ablate or roughen a plurality of smaller sections of the skin 80.

The protruding member 124 can optionally contain treatment material. For example, the protruding members 124 can be generally cylindrical members having a passageway or chamber 127 that holds treatment material. Thus, fluid can be used in combination with treatment material coupled to the tip 34.

With reference to FIGS. 5A through 9, the inner member 124 preferably has a height from the distal surface that is generally less than the height of the outer member 120. In some non-limiting embodiments, the height of the inner member 124 is less than 90%, 70%, 60%, 50%, and ranges encompassing such percentages of the height of the outer member 120. However, in other embodiments, the inner member 124 has a height that is generally greater than the height of the outer member 120. For example, the inner member 124 can have a height that is 10%, 20%, 30%, 40%, 50% greater than the height of the outer member 120. The inner member 124 can thus protrude from the tip 34. A skilled artisan can select a desired height of the inner member 124 and/or the outer member 120 to achieve the desired interaction with the person's skin 80.

FIGS. 10A through 10E illustrate another embodiment of a tip 34 comprising an outer member 120 and a pad 128. FIG. 10E depicts the pad 128 removed from the tip 34. The tip 34 preferably has a mounting surface 227 that is surrounded by the outer member 120. The pad 128 can be permanently or temporarily coupled to the mounting surface 227.

The pad 128 preferably has a distal surface 224 configured to treat a person's skin. In some embodiments, the pad 128 is a disposable pad that comprises treatment material attached thereto. For example, the pad 128 may comprise vitamins, moisturizers, antioxidants, and the like. Preferably, the pad 128 comprises an adhesive proximal side and a distal side 224 including an abrasive surface. The abrasive surface can have grit, a plurality of members (e.g., members similar to the inner members 124 described above), or the like. The pad 128 can be permanently coupled to the mating surface 227 so that the tip 34 can be used for an extended length of time, or for multiple treatments. In alternative embodiments, the tip 34 is removable for maximum flexibility in selecting pad abrasiveness, and also allows the user to make changes to the tip 34 without changing the tip 34 in its entirety. The grit rating of abrasive surface of the distal surface 224 can be selected based on the desired rate of skin removal.

The illustrated pad 128 is generally elliptical and planar. In alternative embodiments, the pad 128 can be polygonal, circular, or have any other shape as desired. The pad 128 can have cutouts 225 that can match the through-holes 114, 122. The cutouts 225 can be aligned with the through-holes 114, 122 when the pad 128 is coupled to the mounting surface 227 of the tip 34, as shown in FIGS. 10A to 10D. The illustrated mounting surface 227 defines a plurality of tip flow channels 229 extending between the through-holes 114,

## 13

122. When the tip 34 is assembled, fluid can flow along the channels 229 between the main body 66 and the pad 128.

Various types of adhesives can be used to temporarily or permanently couple the pad 128 to the mounting surface 227. As used herein, the term “adhesive” is a broad term and includes, but is not limited to, coupling agents, glues, bonding materials, or the like. In some embodiments, for example, waterproof pressure sensitive adhesives are used for releasably coupling the pad 128 to the mounting surface 227. In some embodiments, the pad 128 can be permanently coupled to the mounting surface 227. For example, the pad 128 can be bonded or fused to the main body 66. Additionally or alternatively, snap fittings, fasteners, or other coupling structures can be used to mount the pad 128.

The tip 34 described above can be used for wet or dry modes of operation. As such, the tip 34 can be used for wet exfoliation or dry exfoliation. In some embodiments, the tip 34 is used in a dry mode to remove a desired amount of skin. After removing a desired amount of skin, the tip 34 can be used in a wet mode on the same or different area of the patient's skin. During wet mode, fluid can be passed out of the tip 34 onto the patient's skin. The wet tip 34 can exfoliate, hydrate, and/or perform other types of treatments. Alternatively, the tip 34 can be used in a wet mode and then a dry mode. The sequence of wet and dry modes of operation can be selected based on the type of tip, treatment material, skin condition, and the like.

Although the handpiece assemblies are primarily discussed with respect to use with treatment material, the handpiece assemblies can be used without treatment material, i.e., the handpieces can be used in a dry procedure. Dry procedures can be used for non-hydration procedures and may require less post-procedure clean up.

Various fabrication techniques can be employed to make the tips 34 as mentioned above in connection with FIGS. 11A-11E. In some embodiments, the tips 34 are formed through a molding process, such as an injection or compression molding process. The tips 34 of FIGS. 5A to 5D, for example, can be monolithically formed through an injection molding process. Alternatively, the tip 34 of can have a multi-piece construction, if desired. The tips 34 can be made of polymers, rubbers, metals, or other suitable materials.

The tips 34 can also be fabricated in a multi-step process. For example, the main body 66 and skirt 64 can be formed in a single process. A textured surface (e.g., pad, inner members 124, etc.) can be applied to the main body 66 in a subsequent process. The textured surface can be formed by cutting, embossing, adding material (e.g., a pad, adhesive grit, etc.), a roughening implement, stamping process, or other suitable texturing means.

The tips can have associated treatment materials, including, for example, a medicament. As used herein, the term “medicament” is a broad term and includes, without limitation, growth agents, growth factors or hormones, growth inhibitors, serums, treatment material, cleaners, vitamins, exfoliators, lubricants, or other substances that can be used to treat a patient's skin. The medicament can be associated with the tip 34 by imbedding, overlaying, coating, impregnation, co-mixing, absorption, or other suitable means for associating the medicament with the tip 34. The medicament can be hardened so that it can further enhance massaging and/or abrasion. In some embodiments, the medicament forms hardened grit that can be imbedded on the surface of the tip 34. The grit can work in combination with the inner members 124 to treat a person's skin. If a fluid is used, the fluid can facilitate the release of the medicament from the tip 34. In some embodiments, the medicament comprises or

## 14

more bioactive substances, such as antibiotics, substances for accelerating the healing of the wound, cell proliferation agents, and the like. Such bioactive substances may be desirable because they contribute to the healing of damaged or removed skin, as well as reducing the likelihood of infection.

FIGS. 11A to 11E illustrate different cross-sections of inner members that can be used with the tips illustrated in FIGS. 1-10E. The inner member 124 of FIG. 11A has generally sharp tip 253 for removing tissue. The tip 253 can have any suitable configuration for removing tissue from a patient. FIG. 11B illustrates an inner member 124 that has a pair of cutting edges 253 and a generally trapezoidal shape. FIG. 11C illustrates an inner member 124 that has a surface treatment 255 for treating a person's skin. The surface treatment 255 can be serrations, grooves, grit, roughed surface, protrusions, and the like. The type of surface treatment 255 can be selected based on the procedure to be performed. FIG. 11D illustrates another inner member 124 having a pair of cutting edges 253. The cutting edges 253 are spaced from each other and protrude outwardly. The central portion 257 is generally V-shaped; however, the central portion 257 can have other configurations. For example, FIG. 11E illustrates a central portion 257 that has a curved, semi-circular profile. In alternative embodiments, the inner member 124 can have more than two cutting edges.

The inner members 124 of FIGS. 11A to 11E can be formed by a molding process, such as an injection molding process. Additionally or alternatively, the inner members 124 can be formed by a machining process. For example, at least a portion of the inner member 124 of FIGS. 11D to 11E can be formed through a machining process. In some embodiments, the central portion 257 can be formed by cutting material out of the inner member 124. The fabrication process (e.g., molding, injection molding, compression molding, machining, milling, etc.) can be selected based on the design of the inner members.

Referring again to FIG. 1, the console 12 includes a manifold system 24 that holds containers 26 containing treatment fluids and/or antimicrobial agents. In a preferred embodiment, the console 12 holds four containers 26, three containing different treatment fluids and one containing an antimicrobial agent. In the illustrated embodiment, the largest container 26 holds antimicrobial agent for cleaning and sanitizing the fluid lines of the console 12. The containers 26 can also hold other suitable substances, such as surfactants, disinfectants, sanitizers, and the like, for cleaning and/or sanitizing the skin treatment system 10.

As shown in FIGS. 12 and 13A, the container 26 can be a fluid source such as a bottle comprising a body 262, a neck 264, and a closure assembly 266. The neck 264 includes a threaded neck finish and the closure 266 includes a threaded interior surface, allowing it to screw onto the neck 264. The closure 266 can be permanently or temporarily coupled to the neck 264. The illustrated bottle 26 is a non-refillable, disposable bottle. As used herein, the term “non-refillable” is a broad term that includes, but is not limited to, components that cannot be easily refilled with a treatment material. For example, the illustrated non-refillable bottle 26 cannot be refilled without substantial difficulty.

Bodies 262 of the containers 26 may be formed by stretch blow molding a preform into the desired shape. In other embodiments, the body 262 and a neck 264 can be formed by extrusion blow molding. For example, the bottle of FIG. 13A can be formed by extrusion blow molding. The containers 26 can be made of polymers, thermosets, thermoplastic materials such as polyesters (e.g., polyethylene tere-

15

phthalate (PET)), polyolefins, including polypropylene and polyethylene, polycarbonate, polyamides including nylons, epoxies, and/or acrylics. The material can be virgin or post-consumer/recycled. However, other suitable materials known in the art can also be used.

In some embodiments, including the illustrated embodiment of FIGS. 12 and 13B, the closure 266 is welded (e.g., induction welded) to an upper edge 269 of the neck 264. A sealing member 267 can be interposed between the upper edge of the neck 269 and the closure 266. In some embodiments, the sealing member 267 is made out of a conductive metal, such as aluminum, that preferably does not react with the fluid in the bottle 26. In other embodiments, the seal 267 comprises plastic, such as cellophane, polypropylene, or other suitable material, preferably suitable for coupling to the closure 266 and upper edge 269. In some embodiments, the sealing member 267 comprises metal that is at least partially coated with a polymer, such as polypropylene. Induction welding can be used to couple the polypropylene to the closure 266 and neck 264, both of which can also comprise polypropylene.

FIG. 14A illustrates another embodiment of a bottle 26. The closure 266 includes locking members 268 that engage the neck 264, but do not allow removal of the closure 266 from the bottle 26 when assembled, as shown in FIG. 13B. The locking closure 266 may include a sealing member 267, for example as described above.

In either of the embodiments illustrated in FIGS. 12 through 14B, the closure 266 may then be sealed with a second closure (not shown), creating multi-piece closures. For example, a screw cap can be threaded onto the external threads 273 at the top end of the closure 266. In these embodiments, the treatment fluid inside the bottle 26 may be accessed by puncturing or otherwise breaking the seal 267, for example with an insertion tip assembly 59 (see FIG. 13A).

The insertion tip assembly 59 has an elongate member 161 that comprises a fluid pick up conduit 62 and lancing tip 64 extending from the distal end of the conduit 62. In the illustrated embodiment, the lancing tip 64 is a tubular member having a somewhat sharp distal end. To access treatment fluid in the bottle 26, the lancing tip 64 can be inserted into the closure passageway 73 of the closure 266. The lancing tip 64 can be advanced through the passageway 73 until it breaks the sealing member 267. The elongate member 161 can be sufficiently rigid such that it can break the sealing member 267 without buckling. The elongate member 161 can comprise metal, polymers, plastics, or any suitable material.

The fluid pick up conduit 62 and lancing tip 64 can be slid through the passageway 73 until the stop 91 is spaced from the upper edge of the closure 266. In alternative embodiments, the insertion tip assembly 59 can be slid through the passageway 73 until the stop 91 contacts the upper edge of the closure 266, as shown in FIG. 13B. After the insertion tip assembly 59 and bottle 26 are assembled, as shown in FIG. 13B, the treatment material can be draw upwardly through the lancing tip 64 and the fluid pick up conduit 62. The treatment material can flow through a passageway of the insertion tip assembly 59 and to the manifold assembly 24.

In certain embodiments, the treatment fluid applied from the containers 26 may be selected from the console 12 for a particular treatment or skin type. In one embodiment, the treatment fluid may comprise a skin rejuvenation serum. Skin rejuvenation serum cleans the skin 80 deeply while softening sebum and impurities to aid in extractions. Skin rejuvenation serum also assists in dislodging dead cells for

16

extraction and exfoliation by the tip 34 as well as providing residual hydration that aids in firming and smoothing fine lines, resulting in clean, refined, and ultra-moisturized skin 80. Preferably, a skin rejuvenation treatment serum is active-4™, available from Edge Systems Corp., 2277 Redondo Ave., Signal Hill, CA, 90755, (800) 603-4996. In another embodiment, the treatment fluid may comprise a salicylic acid serum. A salicylic acid serum cleans oily skin deeply while softening sebum and impurities to aid in extraction and exfoliation by the tip 34. Hydration additives in the salicylic acid serum create an ultra-moisturized skin surface, and is blended to remain on the face for the best possible benefit. Preferably, a salicylic acid treatment fluid is Beta-hd™, also available from Edge Systems Corp. In yet another embodiment, the treatment fluid may comprise antioxidants. The antioxidant serum is a hybrid that combats free radicals and environmental damage to the cells. The antioxidant serum is formulated with a blend of the most effective antioxidant ingredients. The antioxidant serum is an absorbable, leave-on service that improves the appearance of age signs as well as texture and clarity. Preferably, an antioxidant treatment fluid is antiox-6™ also available from Edge Systems Corp. The treatment fluids may comprise agents known to be beneficial to skin healing and/or hydration including but not limited to glucosamine, laminaria digitata extract, yeast extract, carbamide, lactic acid, sodium lactate, honey extract, pentylene glycol, spirea ulmaria extract, *Camellia sinensis* leaf (white tea) extract, horse chestnut extract, stabilized vitamins A, B1, B6, B12, C, and E, tocopherol, inositol, calcium panthothenate, linoleic acid, rosemarinus officinalis extract, biotin, and aloins such as anthraquinone glycosides, polysaccharides, sterols, gelonins, and chromones.

A single treatment may comprise the serial use of several treatment fluids from the containers 26. For example, the treatment of acne prone skin may comprise salicylic treatment followed by antioxidant treatment, the treatment of aging skin may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of congestion (e.g., blackheads) may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of damaged skin (e.g., due to medication or smoking) may comprise skin rejuvenator treatment followed by antioxidant treatment, the treatment of skin may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of hyperpigmentation may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of melasma may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of sensitive skin may comprise skin rejuvenator treatment followed by antioxidant treatment, and the treatment of thin skin may comprise salicylic treatment followed by antioxidant treatment. Alternatively, a single treatment may comprise the parallel use of a combination of treatment fluids from the containers 26, for example using a handpiece with a plurality of input lumens 90 as described above. Treatment time with each treatment fluid is preferably about 2 to 20 minutes, but may be longer or shorter depending on the patient, the tip 34 used, and the treatment itself.

The treatment materials can be used for acne (e.g., by removing oils, bacteria, etc.), melasma, damaged skin (e.g., sun damaged skin, burns, free radical damage, etc.), extractions, skin lightening and/or brightening, skin lines (e.g., fine lines, wrinkles, creases, etc.), dry skin, and the like. The

17

treatment materials can improve skin elasticity and overall health of the skin. For example, if the skin is damaged, antioxidants can be applied to damaged area. Accordingly, the skin treatment system 10 can be used to improve the health, appearance, and/or function of a person's skin.

Additionally, the line 20 may be periodically flushed with a fluid (e.g., an antimicrobial fluid, water, etc.) contained in one of the containers 26. Antimicrobial fluids can contain any disinfecting agent compatible with skin including, but not limited to, butylene glycol, phenoxyethanol, and methyl isothiazolinone. Preferably, an antimicrobial fluid is Rinseaway™, available from Edge Systems Corp. The line 20 should be flushed with antimicrobial fluid at least at the end of each service day. Flushing with antimicrobial fluid is more important when the system is not used for consecutive days.

As illustrated in FIG. 1, the console 12 comprises the manifold system 24 designed to draw treatment fluid from at least one of the containers 26 based on user selection. The manifold system 24 may include switches 29, each corresponding to one of the bottles. The switches 29 can be used to control fluid flow from the containers 26. The illustrated switches 29 can be used to turn Off/On to permit or prevent fluid flow from the bottles 26. The illustrated manifold system 24 has a switch corresponding to each bottle 26. As such, the switches can be used to independently control fluid flow from each of the bottles 26. In other embodiments, a single switch can be used to control the flow of treatment fluid from more than one of the bottles 26.

With continued reference to FIG. 1, the button 246 can be operated to release a corresponding bottle 26 from the manifold system 24. FIG. 15A is front perspective view an embodiment in which the manifold system 24 contains quick-release locks connected to the button 246, wherein the quick-release locks capture the containers 26. As illustrated in FIGS. 14B and 14C, the quick-release locks 242 engage the closure 266 when the bottle 26 is inserted into the manifold system 24. When the quick-release lock 242 is manually engaged by a user, for example by pulling the button 246, a slide structure 249 surrounding the closure 266 releases, thereby releasing the bottle 26 from the manifold system 24.

FIG. 15E illustrates the slide structure 249 holding the neck 264 of the bottle 26 in an elongated slot 309. The button 246 can be pushed inwardly (indicated by the arrow 313) so that the neck 264 is positioned within the enlarged aperture 317. The bottle 26 can then slide downwardly out of the manifold system 24. The bottle 26 can be replaced with another bottle 26.

To couple the bottle 26 to the manifold system 24, the closure 266 can be inserted through the aperture 317 of the slide structure 249 when the button 246 is pushed in. Once the closure 266 engages the stop surface 333 (FIG. 15C), the spring 247 can push the slide structure 249 until the flange 335 of the bottle 26 rests on the slide structure 249, as shown in FIG. 15C. In such a position, the manifold system 24 securely holds the bottle 26. The illustrated slide structure 249 has a sloped portion 269 that can cam along the flange 335 as the button 246 moves outwardly. Accordingly, the slide member 249 can push the closure 266 upwardly until the closure 266 is locked with the manifold 24, as shown in FIG. 15C. The quick-release lock 242 is loaded with spring 247 such that the slide structure 249 is biased towards the button 246.

The manifold system 24 can have a modular design so that it can be removed from the console 12. In some embodiments, the manifold system 24 and associated containers 26

18

can be removed and transported away from the console 12. Accordingly, the modular manifold systems can be interchanged to provide treatment flexibility. Alternatively, the manifold system 24 can be permanently mounted to the console 12.

FIGS. 15B and 15C illustrate cross-sectional views of the manifold system 24 taken along lines 15B-15B and lines 15C-15C, respectively. Both FIGS. 15B and 15C show the fluid pick up conduit 62 in operative engagement with the bottle 26 through the seal 267. Suction device(s) is preferably in fluid communication with the fluid pick up conduit 62, and draws fluid out of the bottle 26 through the fluid pick up conduit 62. The fluid can flow through a passageway 161 (see FIG. 15C) extending through the pick up conduit 62. The fluid can flow to and through the lumen 171 towards the line 20. If the switch 29 is off, the fluid from one or more of the upstream bottles can flow along the passage 173. The manifold system 24 then directs the fluid into the line 20.

In certain embodiments, including the embodiment of FIG. 1, the console 12 comprises a computer with display 32. In one embodiment, the display 32 is a user input device comprising a touch screen that controls the computer. In other embodiments, the computer may be controlled by input devices such as a keyboard, keypad, mouse, pointing device, or other input device. The computer controls a variety of functions in the console 12. For example, the computer may control the manifold system 24, and thereby the flow of treatment fluids from the containers 26. In one embodiment, the fluid flowing through the line 20 can be changed by pressing a single button on the touch screen display 32. In another embodiment, the computer contains teaching tutorials that are exhibited on the display 32. In yet another embodiment, the user may change program chips within the computer according to treatment and/or patient. In still another embodiment, the computer records patient and treatment data, for example data gathered during treatment.

The console 12 can also comprise a mechanical system for controlling fluid flow from the containers to the handpiece. One or more pumps, valves, fluid lines, and the like can cooperate to deliver fluid from the containers to the handpiece. The console 12 can be powered pneumatically, electrically, or by any other suitable powering means. The mechanically drive console 12 can have manual controls for controlling fluid flow to the handpiece.

The console 12 can also comprise additional handpieces suitable for other types of skin treatment. These additional handpieces can be used for pre-treatment or post-treatment in combination with other modalities. For example, the console 12 may include a handpiece for diamond tip abrasion, or "crystal-free" microdermabrasion, as described above. Such a handpiece may be useful for more aggressive treatments, in addition to treatment with the handpiece assembly 18. The diamond tips can range from fine to extra coarse.

In some embodiments, the console 12 comprises a handpiece including at least one light emitting diode (LED). Light therapy has been shown to improve skin. For example, red light between about 600 and about 700 nanometers and infrared LED light between about 700 and about 1,000 nanometers reduces the appearance of fine lines and superficial hyperpigmentation. For another example, blue LED light at about 430 nanometers improves the appearance of oily and acne-prone skin. Other benefits of light therapy include promotion of collagen production, increased circulation and moisture retention, smoothing of skin texture, and improvement of skin firmness and resilience.

19

The console 12 can comprise handpieces for vacuum therapy such as lymphatic drainage and cellulite massage. Vacuum therapy enhances the effects of treatment with the handpiece assembly 18 and LED light therapy. Preferably, the vacuum therapy handpieces are sized appropriately for facial massage and body massage. An example of a multi-modality protocol using a plurality of handpieces comprises diamond tip abrasion, treatment with handpiece assembly 18 and at least one treatment fluid from containers 26, vacuum therapy, red light therapy, and application of sunscreen, for example at a minimum skin protection factor (SPF) of 15. The various modalities may be included and ordered by the user depending on the desired outcome of the overall treatment.

The console 12 optionally includes any of a plurality of additional features. For example, a digital camera may be used to take pictures of the patient before and after treatment, and the pictures may be stored on the computer. The computer may hold client medical and treatment records. The computer may be connected to a network. The console 12 may store disks. The console 12 may include an ultrasound unit. The console 12 may include a stimulator, such as an electrical stimulator. The console 12 may include an iontophoresis handpiece. The number of additional features is limitless when considering the range of features that a user may wish to incorporate with the treatment provided by the handpiece assembly 18.

FIG. 16 depicts another embodiment of the skin treatment system 10, which may be generally similar to the embodiment illustrated in FIG. 1, except as further detailed below. Where possible, similar elements are identified with identical reference numerals in the depiction of the embodiment of FIG. 1.

The line 20 includes an output line 50 for removing waste from the handpiece assembly 18 and an input line 52 for delivering treatment material to the handpiece assembly 18. A valve 300 can be disposed along the input line 52 to inhibit backflow of treatment material. The console 12 can pump treatment material through the input line 52 to the handpiece assembly 18 when the handpiece assembly 18 is applied to the person's skin, as detailed above. The fluid flow through the input line 52 can be reduced or stopped so that the handpiece assembly 18 can be removed from the patient's skin. The valve 300 can inhibit the flow of fluid through the input line 52 towards the console 12. A desired amount of treatment material can therefore be contained in the handpiece assembly 18 and the section 310 of the input tubing 52 extending between the valve 300 and the handpiece assembly 18. When the handpiece assembly 18 is applied to a patient's skin, a vacuum can be applied to the output line 50. The vacuum can draw the treatment material out of the handpiece assembly 18 without a substantial or noticeable delay.

In some embodiments, the valve 300 can be a one-way valve, such as a duckbill valve, check valve, or other type of valve for inhibiting fluid flow. In alternative embodiments, the valve 300 can comprise a plurality of valves (e.g., one-way valves, flow regulators, adjustable valves, etc.).

FIG. 17 is a cross-sectional view of the line 20. The input and output lines 50, 52 can have different or similar cross sectional flow areas. The illustrated output line 50 has a passageway 312 with a diameter that is less than the diameter of a passageway 314 of the input line 52. Accordingly, a relatively large slug of treatment material can be stored in the section 310 extending distally from the valve 300 to the handpiece assembly 18. The slug can be quickly

20

delivered out of the handpiece assembly 18 once the handpiece assembly is applied to a patient's skin as detailed above.

In some embodiments, the section 310 of the output line 50 has a length L greater than 6 inches, 12 inches, 18 inches, 24 inches, and ranges encompassing such lengths. In some embodiments, the section 310 of the output line 50 has a length L greater than 24 inches, 30 inches, 36 inches, and ranges encompassing such lengths. The passageway 312 can have a cross-sectional area that is at least 10%, 30%, 50%, 75%, or 100% greater than the cross-sectional area of the passageway 314. The length L and the diameters of the passageways 312, 314 can be selected based on the desired amount of treatment material to be stored in the line 20, delivery and removal rates.

FIGS. 18 and 19 illustrate a modular handpiece assembly 360 having a cartridge 362 containing treatment material. The illustrated handpiece assembly 360 can be used to deliver treatment material from the cartridge 362. The main body 30 can have a pump for pressuring the treatment material. In one embodiment, the fluid control device includes a power supply, such as a battery, which provides power to electrical components (e.g., pumps or valves) of the handpiece assembly 360. The power supply can be a battery that is preferably disposed within the main body 30 of the handpiece assembly 360. In one arrangement, the battery is a rechargeable battery that can be connected to and recharged by an AC power supply, such as a typical residential electrical outlet. Alternatively, the handpiece assembly 360 can be directly powered by an AC power supply. The power supply can provide power to several components of the handpiece assembly 360. For example, the power supply can provide power to a plurality of fluid control devices 330 and/or a flow control unit. A control switch 371 can be used to turn the handpiece assembly 360 Off/On and/or control the output of the handpiece assembly 360.

In operation, the cartridge 362 can be inserted into the main body 30. The handpiece assembly 360 can be applied to a patient's skin to deliver treatment material from the cartridge 362 to the patient's skin. After delivering a desired amount of treatment material, the cartridge 362 can be separated from the main body 30. The cartridge 362 can be a one-use or multi-use cartridge. For example, the cartridge can be a non-refillable disposable cartridge.

The tip 34 can also be used to remove hair or perform other skin treatments. For example, the tip 34 can include one or more razor blades and may be configured to apply a treatment material (e.g., antioxidants, vitamins, serums, growth agents, etc.) to the skin during the shaving process. In such embodiments, the main body 30 can be an elongated handle that is connected to a transversely extending elongate tip 34. In some embodiments, the handpiece assembly can be in the form of a disposable handheld razor. The treatment material can reduce or substantially eliminate problems associated with wet or dry shaving systems. These treatment materials may be applied prior to, during, before, and/or after shaving.

The articles disclosed herein may be formed through any suitable means. The various methods and techniques described above provide a number of ways to carry out the invention. Of course, it is to be understood that not necessarily all objectives or advantages described may be achieved in accordance with any particular embodiment described herein. Thus, for example, those skilled in the art will recognize that the methods may be performed in a manner that achieves or optimizes one advantage or group of

## 21

advantages as taught herein without necessarily achieving other objectives or advantages as may be taught or suggested herein.

Furthermore, the skilled artisan will recognize the interchangeability of various features from different embodiments disclosed herein. Similarly, the various features and steps discussed above, as well as other known equivalents for each such feature or step, can be mixed and matched by one of ordinary skill in this art to perform methods in accordance with principles described herein. Additionally, the methods which are described and illustrated herein are not limited to the exact sequence of acts described, nor are they necessarily limited to the practice of all of the acts set forth. Other sequences of events or acts, or less than all of the events, or simultaneous occurrence of the events, may be utilized in practicing the embodiments of the invention.

Although the invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

What is claimed is:

1. A system for treating skin, the system comprising:
  - a console configured to receive a first container and at least one additional container;
  - a handpiece configured to contact skin tissue of a subject; and
  - a block in the console, wherein the block is:
    - configured to selectively receive fluid from the first container when the first container is connected to the console;
    - configured to selectively receive fluid from the at least one additional container when the at least one additional container is connected to the console; and,
    - configured to selectively be in fluid communication with the handpiece through a first conduit when the handpiece is connected to the console;
  - a vacuum source, wherein the console comprises the vacuum source; and
  - wherein the handpiece is configured to be in fluid communication with the vacuum source through a second conduit when the handpiece is connected to the console;
  - wherein when the handpiece, the first container, the at least one additional container and a waste container are each connected to the console, the first container contains a first treatment fluid, and the at least one additional container contains an additional treatment fluid, the handpiece is in fluid communication with the vacuum source and the waste container through the second conduit; and
  - the system is configured to deliver the first treatment fluid contained in the first container and the additional treatment fluid contained in the at least one additional container to the handpiece sequentially.
2. The system of claim 1, wherein the at least one additional container comprises a second container and a third container such that the console is configured to receive at least three containers.
3. The system of claim 2,
  - wherein when the handpiece is connected to the console and the first container, the second container and the third container each contains fluid and is connected to the console, the system is configured to deliver to the handpiece one at a time fluid contained in the first

## 22

container, fluid contained in the second container, and fluid contained in the third container.

4. The system of claim 1, further comprising a computing device configured to control at least one function of the system.
5. The system of claim 4, further comprising a user input device to select a flow of fluids from the first container and the at least one additional container to the handpiece.
6. The system of claim 5, wherein the user input device comprises a touch screen.
7. The system of claim 6, further comprising a display.
8. The system of claim 1, wherein the block is configured to control a flow of the first treatment fluid contained in the first container and the additional treatment fluid contained in the at least one additional container into the block with a valve when the first container and the at least one additional container are connected to the console.
9. The system of claim 1, wherein the system is configured to control a flow of the first treatment fluid contained in the first container to the handpiece through the block when each of the first container and the handpiece is connected to the console.
10. The system of claim 9, wherein the system is configured to separately control a flow of a second treatment fluid contained in the at least one additional container to the handpiece through the block when each of the first container, the at least one additional container, and the handpiece are connected to the console.
11. A skin treatment apparatus comprising:
  - a console that includes a fluid control member that is configured to be in fluid communication with at least a first container and a second container when the first container and the second container are connected to the fluid control member;
  - a handpiece assembly configured to contact a skin surface of a subject;
  - a waste conduit configured to be in fluid communication with the handpiece assembly and a vacuum source to move waste away from the handpiece assembly when the waste conduit and the handpiece assembly are each connected to the console; and
  - wherein when each of the first container and the second container are connected to the console, the fluid control member is configured to be in fluid communication with each of the first container and the second container;
  - wherein when the handpiece assembly is connected to the console, the fluid control member is configured to be in fluid communication with the handpiece assembly;
  - wherein when (i) each of the first container and the second container contains treatment material, (ii) the first container and the second container are connected to the console, and (iii) the handpiece assembly is connected to the console, the skin treatment apparatus is configured to selectively draw treatment material from the first container or the second container to the handpiece assembly using, at least in part, a vacuum created along a distal end of the handpiece assembly by the vacuum source.
12. The skin treatment apparatus of claim 11, wherein treatment material from the first container and the second container are configured to be drawn to the handpiece assembly sequentially.
13. The skin treatment apparatus of claim 11, wherein treatment material from the first container and the second container are configured to be drawn the handpiece assembly simultaneously.

## 23

14. The skin treatment apparatus of claim 11, wherein the console comprises the vacuum source.

15. The skin treatment apparatus of claim 11, wherein the skin treatment apparatus is configured to deliver a single treatment material from the first container to a patient's skin.

16. The skin treatment apparatus of claim 11, wherein the treatment material in the first container is a skin treatment fluid.

17. The skin treatment apparatus of claim 11, further comprising a computing device configured to control at least one function of the skin treatment apparatus.

18. The skin treatment apparatus of claim 17, further comprising a user input device to facilitate control of a flow of treatment materials from at least one of the first container and the second container to the handpiece assembly.

19. The skin treatment apparatus of claim 18, wherein the user input device comprises a touch screen.

20. The skin treatment apparatus of claim 19, further comprising a display.

21. The skin treatment apparatus of claim 11, wherein the fluid control member includes a first switch corresponding to the first container and a second switch corresponding to the second container, the first switch and the second switch configured to permit or prevent flow from the first container and the second container to independently control flow from each of the first container and the second container.

22. A system for treating skin, the system comprising:

a console configured to receive a first container and at least one additional container;

a collection lumen configured to be in fluid communication with the first container and the at least one additional container when the first container and the at least one additional container are connected to the console; and

a handpiece having a working end, the working end of the handpiece being configured to contact skin tissue of a subject during use;

wherein the working end of the handpiece is configured to be placed in fluid communication with a vacuum source to create a suction force along a distal end of the handpiece when the vacuum source is activated and the handpiece is connected to the console and wherein the working end of the handpiece is configured to be placed in fluid communication with the first container or the at least one additional container through the collection lumen; and

a supply conduit that places the collection lumen in fluid communication with the working end of the handpiece when the handpiece is connected to the console;

wherein each of the first container and the at least one additional container includes treatment materials, and wherein treatment materials from the first container and the at least one additional container are configured to be delivered to the supply conduit sequentially when the first container and the at least one additional container are connected to the console.

23. The system of claim 22, wherein the console comprises the vacuum source; wherein the handpiece is in fluid communication with the vacuum source and a waste container through a waste conduit when the handpiece and the waste container are connected to the console; and

wherein the system is configured to deliver a first treatment fluid contained in the first container and an additional treatment fluid contained in the at least one additional container to the handpiece sequentially or

## 24

simultaneously when the first container and the at least one additional container are connected to the console.

24. The system of claim 22, further comprising a computing device configured to control at least one function of the system.

25. The system of claim 24, further comprising a user input device to facilitate control of a flow of fluids from the first container and the at least one additional container to the handpiece.

26. A system for treating skin, the system comprising:

a console configured to receive a first container and at least one additional container;

a handpiece configured to contact skin tissue of a subject; and

a block in the console, wherein the block is: configured to selectively receive fluid from the first container when the first container is connected to the console;

configured to selectively receive fluid from the at least one additional container when the at least one additional container is connected to the console; and,

configured to selectively be in fluid communication with the handpiece through a first conduit when the handpiece is connected to the console; and

a vacuum source;

wherein the handpiece is configured to be in fluid communication with the vacuum source through a second conduit when the handpiece is connected to the console;

wherein the at least one additional container comprises a second container and a third container such that the console is configured to receive at least three containers; and

wherein when the handpiece is connected to the console and the first container, the second container and the third container each contains fluid and is connected to the console, the system is configured to deliver to the handpiece one at a time fluid contained in the first container, fluid contained in the second container, and fluid contained in the third container.

27. The system of claim 26, wherein the system is configured to combine in the block a first treatment fluid contained in the first container and an additional treatment fluid contained in the at least one additional container to create a mixture of treatment fluid.

28. The system of claim 26,

wherein the console comprises the vacuum source; and wherein the handpiece is in fluid communication with the vacuum source and a waste container through the second conduit when the handpiece is connected to the console.

29. The system of claim 26, wherein the system is configured to deliver a first treatment fluid contained in the first container and an additional treatment fluid contained in the at least one additional container to the handpiece sequentially when the handpiece is connected to the console.

30. The system of claim 26, further comprising a computing device configured to control at least one function of the system.

31. The system of claim 30, further comprising a user input device to select a flow of fluids from the first container and the at least one additional container to the handpiece.

32. The system of claim 31, wherein the user input device comprises a touch screen.

33. The system of claim 32, further comprising a display.

34. The system of claim 26, wherein the block is configured to control a flow of a first treatment fluid contained in

## 25

the first container and an additional treatment fluid contained in the at least one additional container into the block with a valve when the first container and the at least one additional container are connected to the console.

35. The system of claim 26, wherein the system is configured to control a flow of a first treatment fluid contained in the first container to the handpiece through the block when each of the first container and the handpiece is connected to the console.

36. The system of claim 35, wherein the system is configured to separately control a flow of a second treatment fluid contained in the at least one additional container to the handpiece through the block when each of the first container, the at least one additional container, and the handpiece are connected to the console.

37. A system for treating skin, the system comprising:  
a console configured to receive a first container and at least one additional container;

a handpiece configured to contact skin tissue of a subject; and

a block in the console, wherein the block is:  
configured to selectively receive fluid from the first container when the first container is connected to the console;

configured to selectively receive fluid from the at least one additional container when the at least one additional container is connected to the console; and,

configured to selectively be in fluid communication with the handpiece through a first conduit when the handpiece is connected to the console; and

a vacuum source;

wherein the handpiece is configured to be in fluid communication with the vacuum source through a second conduit when the handpiece is connected to the console;

wherein the system is configured to control a flow of a first treatment fluid contained in the first container to the handpiece through the block when each of the first container and the handpiece is connected to the console; and

## 26

wherein the system is configured to separately control a flow of a second treatment fluid contained in the at least one additional container to the handpiece through the block when each of the first container, the at least one additional container, and the handpiece are connected to the console.

38. The system of claim 37, wherein the system is configured to combine in the block the first treatment fluid contained in the first container and the second treatment fluid contained in the at least one additional container to create a mixture of treatment fluid.

39. The system of claim 37,

wherein the console comprises the vacuum source; and wherein the handpiece is in fluid communication with the vacuum source and a waste container through the second conduit when the handpiece is connected to the console.

40. The system of claim 37, wherein the system is configured to deliver the first treatment fluid contained in the first container and the second treatment fluid contained in the at least one additional container to the handpiece sequentially when the handpiece is connected to the console.

41. The system of claim 37, further comprising a computing device configured to control at least one function of the system.

42. The system of claim 41, further comprising a user input device to select a flow of fluids from the first container and the at least one additional container to the handpiece.

43. The system of claim 42, wherein the user input device comprises a touch screen.

44. The system of claim 43, further comprising a display.

45. The system of claim 37, wherein the block is configured to control the flow of the first treatment fluid contained in the first container and the second treatment fluid contained in the at least one additional container into the block with a valve when the first container and the at least one additional container are connected to the console.

\* \* \* \* \*